Amsurg (AMSG) 10-Q 4 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 02, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	895,930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		54,810,106

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 74,105	$ 106,660
Restricted cash and marketable securities	12,794	13,506
Accounts receivable, net of allowance of $208,780 and $167,411, respectively	375,352	337,330
Supplies inventory	21,980	21,406
Prepaid and other current assets	74,565	75,771
Total current assets	558,796	554,673
Property and equipment, net	204,922	189,168
Investments in unconsolidated affiliates	179,056	169,170
Goodwill	4,175,008	3,970,210
Intangible assets, net	1,679,275	1,594,637
Other assets	46,263	21,450
Total assets	6,843,320	6,499,308
Liabilities and Equity
Current portion of long-term debt	20,772	20,377
Accounts payable	30,721	32,561
Accrued salaries and benefits	186,908	202,537
Accrued interest	30,400	30,480
Other accrued liabilities	92,571	119,237
Total current liabilities	361,372	405,192
Long-term debt	2,581,043	2,357,956
Deferred income taxes	743,447	699,498
Other long-term liabilities	119,478	96,183
Commitments and contingencies
Noncontrolling interests – redeemable	177,845	175,732
Equity:
Preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632	166,632
Common stock, no par value, 120,000 shares authorized, 54,816 and 54,294 shares issued and outstanding, respectively	1,356,829	1,345,418
Retained earnings	853,817	781,413
Total AmSurg Corp. equity	2,377,278	2,293,463
Noncontrolling interests – non-redeemable	482,857	471,284
Total equity	2,860,135	2,764,747
Total liabilities and equity	$ 6,843,320	$ 6,499,308

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 208,780	$ 167,411
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,725,000	1,725,000
Preferred stock, shares outstanding	1,725,000	1,725,000
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	54,816,000	54,294,000
Common stock, shares outstanding	54,816,000	54,294,000

Consolidated Statements Of Earn

Consolidated Statements Of Earnings - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues	$ 859,832	$ 707,733	$ 1,678,118	$ 1,345,930
Provision for uncollectibles			(207,046)	(144,514)
Net revenue	758,499	641,950	1,483,177	1,212,395
Operating expenses:
Salaries and benefits	404,011	320,396	813,850	622,575
Supply cost	49,703	45,790	96,666	88,374
Other operating expenses	111,145	105,002	218,827	195,572
Transaction costs	5,135	1,982	6,525	3,453
Depreciation and amortization	30,054	23,612	59,126	46,430
Total operating expenses	600,048	496,782	1,194,994	956,404
Net gain (loss) on disposals and deconsolidations	2,595	(3,035)	2,595	(3,258)
Equity in earnings of unconsolidated affiliates	7,351	3,989	13,930	6,640
Operating income	168,397	146,122	304,708	259,373
Interest expense, net	31,913	30,182	62,723	60,429
Earnings before income taxes	136,484	115,940	241,985	198,944
Income tax expense	33,365	25,193	54,162	39,442
Net earnings	103,119	90,747	187,823	159,502
Less net earnings attributable to noncontrolling interests	57,050	57,072	110,891	104,789
Net earnings attributable to AmSurg Corp. shareholders	46,069	33,675	76,932	54,713
Preferred stock dividends	(2,264)	(2,264)	(4,528)	(4,528)
Net earnings attributable to AmSurg Corp. common shareholders	$ 43,805	$ 31,411	$ 72,404	$ 50,185
Net earnings per share attributable to common shareholders:
Earnings Per Share, Basic	$ 0.82	$ 0.66	$ 1.35	$ 1.05
Earnings Per Share, Diluted	$ 0.80	$ 0.65	$ 1.34	$ 1.05
Weighted average number of shares and share equivalents outstanding:
Basic (in shares)	53,739	47,678	53,702	47,625
Diluted (in shares)	57,327	48,099	57,229	48,002
Physician Services [Member]
Provision for uncollectibles	$ (101,333)	$ (65,783)	$ (194,941)	$ (133,535)
Net revenue	$ 438,752	$ 330,959	$ 856,296	$ 617,494

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Mandatory Convertible Preferred Stock [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
Balance at Dec. 31, 2014		$ 885,393	$ 166,632	$ 627,522	$ 418,684	$ 2,098,231	$ 184,099
Balance (in shares) at Dec. 31, 2014		48,113,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 159,502			54,713	33,117	87,830	71,672
Issuance of restricted common stock (in shares)		314,000
Cancellation of restricted common stock (in shares)		(7,000)
Stock options exercised		$ 2,080				2,080
Stock options exercised (in shares)		90,000
Stock repurchased	$ (3,700)	$ (3,684)				(3,684)
Stock repurchased (in shares)	(67,000)	(67,000)
Share-based compensation		$ 7,592				7,592
Tax benefit related to exercise of share-based awards		3,533				3,533
Dividends paid on preferred stock				(4,528)		(4,528)
Acquisitions and other transactions impacting noncontrolling interests		599			59,888	60,487	(408)
Distributions to noncontrolling interests, net of capital contributions					(30,989)	(30,989)	(69,819)
Disposals and other transactions impacting noncontrolling interests		(2,194)			2,229	35	(367)
Balance at Jun. 30, 2015		$ 893,319	$ 166,632	677,707	482,929	2,220,587	185,177
Balance (in shares) at Jun. 30, 2015		48,443,000	1,725,000
Balance at Dec. 31, 2015	$ 2,764,747	$ 1,345,418	$ 166,632	781,413	471,284	2,764,747	175,732
Balance (in shares) at Dec. 31, 2015		54,294,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 187,823			76,932	36,046	112,978	74,845
Issuance of restricted common stock (in shares)		587,000
Cancellation of restricted common stock (in shares)		(7,000)
Stock options exercised		$ 450				450
Stock options exercised (in shares)	19,718	20,000
Stock repurchased	$ (5,700)	$ (5,688)				(5,688)
Stock repurchased (in shares)	(77,780)	(78,000)
Share-based compensation		$ 15,068				15,068
Tax benefit related to exercise of share-based awards		3,734				3,734
Dividends paid on preferred stock				(4,528)		(4,528)
Acquisitions and other transactions impacting noncontrolling interests		780			13,584	14,364	4,013
Distributions to noncontrolling interests, net of capital contributions					(38,149)	(38,149)	(77,158)
Disposals and other transactions impacting noncontrolling interests		(2,933)			92	(2,841)	413
Balance at Jun. 30, 2016	$ 2,860,135	$ 1,356,829	$ 166,632	$ 853,817	$ 482,857	$ 2,860,135	$ 177,845
Balance (in shares) at Jun. 30, 2016		54,816,000	1,725,000

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net earnings	$ 187,823	$ 159,502
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	59,126	46,430
Amortization of deferred loan costs	4,279	4,155
Provision for uncollectibles	207,046	144,514
Net (gain) loss on disposals and deconsolidations	(2,595)	3,258
Share-based compensation	15,068	7,592
Excess tax benefit from share-based compensation	(3,734)	(3,533)
Deferred income taxes	20,987	2,699
Equity in earnings of unconsolidated affiliates	(13,930)	(6,640)
Net change in fair value of contingent consideration	(2,598)	6,410
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(228,374)	(157,056)
Supplies inventory	(412)	(110)
Prepaid and other current assets	(23,744)	30,327
Accounts payable	(3,347)	(696)
Accrued expenses and other liabilities	(28,204)	12,648
Other, net	7,714	1,895
Net cash flows provided by operating activities	195,105	251,395
Cash flows from investing activities:
Acquisitions and related expenses	(281,113)	(196,032)
Acquisition of property and equipment	(37,618)	(32,665)
Proceeds from sale of interests in surgery centers	25	0
Purchases of marketable securities	(498)	(1,245)
Maturities of marketable securities	2,738	2,988
Other	(8,749)	(1,987)
Net cash flows used in investing activities	(325,215)	(228,941)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	317,151	7,795
Repayment on long-term borrowings and revolving credit facility	(98,763)	(10,288)
Distributions to noncontrolling interests	(115,589)	(101,033)
Proceeds from issuance of common stock upon exercise of stock options	450	2,080
Repurchase of common stock	(5,688)	(3,684)
Other	(6)	886
Net cash flows provided by (used in) financing activities	97,555	(104,244)
Net decrease in cash and cash equivalents	(32,555)	(81,790)
Cash and cash equivalents, beginning of period	106,660	208,079
Cash and cash equivalents, end of period	74,105	126,289
Supplemental cash flow information:
Interest payments	58,788	56,252
Income tax paid, net of refunds	$ 45,726	$ 7,772

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all normal recurring adjustments, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in AmSurg Corp.'s (Company) Annual Report on Form 10-K for the fiscal year ended December 31, 2015 . Ambulatory Services The Company, through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers). All LLCs and LPs are referred to herein as “partnerships” and “partners,” respectively. The Company has variable interests in the partnerships through its equity ownership interests. Each partnership is considered a variable interest entity (VIE) due to its structure as a limited partnership or functional equivalent under Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2015-02 “Consolidations (Topic 810) - Amendments to the Consolidation Analysis,” which was adopted effective January 1, 2016. For those partnerships in which the Company’s ownership interest is 51% or greater, the Company is considered the primary beneficiary. The Company is the primary beneficiary due to 1) ownership interest, operating agreements allowing the Company to govern the day-to-day activities, and the Company’s position as the managing member or general partner and 2) the Company's obligation to absorb losses or the right to receive returns proportionate to its equity interest in the partnerships. For the 24 partnerships in which the Company’s ownership interest is less than 51%, the Company is not deemed the primary beneficiary and therefore those partnerships are not consolidated with the exception of 2 partnerships which are consolidated because the Company holds substantive participation rights and has the obligation to absorb losses or right to receive returns proportionate to its equity interest in the partnerships. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated partnerships. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net earnings attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions when there is no change in control; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis. Physician Services The Company, through its wholly-owned subsidiary Sheridan Healthcare, is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. The Company focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, the Company is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. The Company also provides physician services and manages office-based practices in the areas of pain management, gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which the Company has management arrangements. The Company's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned subsidiaries. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “ Consolidations. ” Variable Interest Entities For its PCs and certain of its partnerships, the Company is considered the primary beneficiary of the variable interest entities and consolidates under the Variable Interest Model in ASC 810. The total assets of the VIEs, which are included in the accompanying consolidated balance sheets, as of June 30, 2016 and December 31, 2015 , were $780.5 million and $740.1 million , respectively, and the total liabilities of the VIEs were $297.7 million and $299.0 million , respectively. Included in total assets as of June 30, 2016 and December 31, 2015 , respectively, were $178.6 million and $176.8 million of assets which were restricted to use and could only be used to settle the obligations of the VIE. The creditors of the VIE have no recourse to the Company, with the exception of $18.2 million and $21.7 million of debt guaranteed by the Company at June 30, 2016 and December 31, 2015 , respectively. The restricted assets and obligations, which are either restricted for use in the VIE or the creditor did not have recourse to the Company, generally consisted of the portion of assets and liabilities attributable to the Company's non-controlling partners. The Company also has certain equity interests in unconsolidated affiliates which meet the definition of a variable interest entity. The Company has a variable interest in these investments through its equity interests; however, the Company is not the primary beneficiary of these entities as it holds 50% or less of the voting rights and does not have the power to direct the activities that most significantly impact the entities' economic performance as a result of the Company's shared or lack of control. As a result, the Company has accounted for these investments under the equity method of accounting. The Company's investment in these entities was $179.1 million and $169.2 million as of June 30, 2016 and December 31, 2015 , respectively, and is reflected in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates. The Company has recorded its share of the earnings of these investments of $7.4 million and $4.0 million as a component of equity in earnings of the unconsolidated affiliates in the accompanying statements of earnings during the three months ended June 30, 2016 and 2015 , respectively, and $13.9 million and $6.6 million during the six months ended June 30, 2016 and 2015 , respectively. The Company recognized management and billing fees associated with these investments totaling $5.3 million and $3.8 million during the three months ended June 30, 2016 and 2015 , respectively, and $11.6 million and $7.2 million during the six months ended June 30, 2016 and 2015 , respectively, which are included in net revenue in the accompanying consolidated statements of earnings. The Company has also recorded receivables from these entities in the amount of $9.2 million and $6.0 million as of June 30, 2016 and December 31, 2015 , respectively. These receivables are included in the other current assets in the accompanying consolidated balance sheets. Restricted Cash and Marketable Securities As of June 30, 2016 and December 31, 2015 , the Company had $29.9 million and $27.4 million , respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets the majority of which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $17.1 million and $13.9 million as of June 30, 2016 and December 31, 2015 , respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of June 30, 2016 and December 31, 2015 , the Company had $0.5 million and $2.7 million , respectively, included in restricted cash and marketable securities, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Reclassifications Certain prior year amounts in the accompanying consolidated financial statements have been reclassified to reflect the adoption of ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” as discussed further under “Recent Accounting Pronouncements.” The impact of the reclassification made to prior period balance sheet is presented below (in thousands). December 31, 2015 Consolidated Balance Sheet: Previously reported Reclassification Revised Intangible assets, net $ 1,641,811 $ (47,174 ) $ 1,594,637 Long-term debt $ 2,405,130 $ (47,174 ) $ 2,357,956 Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. In 2016, the FASB issued the following ASUs to provide entities further clarity on the application of ASU 2014-09: • ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” • ASU 2016-10 “Identifying Performance Obligations and Licensing” • ASU 2016-12 “Narrow-Scope Improvements and Practical Expedients” The guidance in ASU 2014-09 and the subsequently related ASUs will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance made amendments to the consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities are considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company adopted this standard effective January 1, 2016 and applied the adoption retrospectively. The adoption of the standard did not result in a change of consolidated subsidiaries nor did it result in any impact to the Company's consolidated financial position, results of operations or cash flows as of and for the three months ended March 31, 2016 or for any previous period. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.” ASU 2015-03 amended current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporated into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards were effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2016 and accordingly, reclassified $47.2 million of deferred debt issuance costs from intangible assets, net to a reduction in long-term debt at December 31, 2015, in the accompanying balance sheets (see reclassification above). In February 2016, the FASB issued ASU No. 2016-02, “Leases” which amends existing accounting standards for lease accounting, including requiring lessees to recognize most leases on the balance sheet and making changes to lessor accounting. The standard is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The new standard requires a modified retrospective application for all leases existing at, or entered into, after the date of initial application, with an option to use certain transition relief. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” which will change how companies account for certain aspects of share-based payments to employees by requiring companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combinations	Business Combinations On June 15, 2016, the Company entered into a definitive merger agreement with Envision Healthcare Holdings, Inc. (Envision). Pursuant to the merger agreement, AmSurg Corp. will change its state of incorporation from Tennessee to Delaware by merging AmSurg Corp. with and into New Amethyst Corp. (New Amethyst), a newly-formed Delaware corporation and a wholly-owned subsidiary of AmSurg Corp., with New Amethyst being the surviving corporation. AmSurg Corp. shareholders will receive one share of New Amethyst common stock for each share of AmSurg Corp. common stock owned and one share of New Amethyst mandatory convertible preferred stock for each share of AmSurg Corp. mandatory convertible preferred stock owned. Following the merger of AmSurg and New Amethyst, Envision will merge with and into New Amethyst, with New Amethyst being the surviving corporation. If the merger is completed, Envision stockholders will receive 0.334 shares of New Amethyst common stock for each share of Envision common stock owned (the Exchange Ratio). The Exchange Ratio is fixed and will not be adjusted to reflect stock price changes prior to the closing. Upon completion of the merger, former Envision stockholders will own approximately 53% of the then outstanding New Amethyst common stock (on a fully diluted basis), including preferred shares. The value of the merger consideration to be received will fluctuate with the market value of AmSurg common stock and Envision common stock until the merger is completed. The merger is currently expected to be completed in the fourth quarter of 2016 and is subject to customary closing conditions, including obtaining regulatory approval and approval from the common shareholders of both AmSurg and Envision. Upon completion of the merger, New Amethyst will change its name to “Envision Healthcare Corporation.”

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2016
Revenue Recognition [Abstract]
Revenue Recognition	Revenue Recognition Ambulatory Services Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor. Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During each of the six months ended June 30, 2016 and 2015 , the Company derived approximately 26% of its ambulatory services net revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Physician Services Physician services revenues primarily consist of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors. The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections. The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries). Net revenue for the physician services segment consists of the following major payors (dollars in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Medicare $ 61,775 14 % $ 45,967 14 % $ 120,549 14 % $ 87,296 14 % Medicaid 30,698 7 19,298 6 61,523 7 37,878 6 Commercial and managed care 337,553 77 254,481 77 661,724 77 474,599 77 Self-pay 71,648 16 45,298 14 133,365 16 88,569 14 Net fee for service revenue 501,674 114 365,044 110 977,161 114 688,342 111 Contract and other revenue 38,411 9 31,698 10 74,076 9 62,687 10 Provision for uncollectibles (101,333 ) (23 ) (65,783 ) (20 ) (194,941 ) (23 ) (133,535 ) (22 ) Net revenue for physician services $ 438,752 100 % $ 330,959 100 % $ 856,296 100 % $ 617,494 100 %

Accounts Receivable

Accounts Receivable	6 Months Ended
	Jun. 30, 2016
Receivables [Abstract]
Accounts Receivable	Accounts Receivable The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts analysis for its physician services segment quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous twelve month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates, if any, are charged or credited to the consolidated statements of operations in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third-party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows. Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statements of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statements of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statements of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for ambulatory services is included in other operating expenses and was $6.3 million and $12.1 million for the three and six months ended June 30, 2016 , respectively, and $4.7 million and $11.0 million for the three and six months ended June 30, 2015 , respectively. Bad debt expense related to physician services was $101.3 million and $194.9 million for the three and six months ended June 30, 2016 , respectively, and $65.8 million and $133.5 million for the three and six months ended June 30, 2015 , respectively. At June 30, 2016 and December 31, 2015 , allowances for doubtful accounts were $208.8 million and $167.4 million , respectively. The increase in the allowance for doubtful accounts is primarily a result of having a full quarter of operations for acquisitions completed during the fourth quarter of 2015 . At June 30, 2016 and December 31, 2015 , approximately 82% and 80% , respectively, of the Company’s allowance for doubtful accounts was related to fee for service patient receivables associated with the physician services segment. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors, and by the geographic dispersion of the Company's operations.

Acquisitions and Disposals

Acquisitions and Disposals	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Acquisitions and Disposals	Acquisitions and Disposals The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Ambulatory Services Activity During each of the six months ended June 30, 2016 and 2015 , the Company, through a wholly-owned subsidiary, acquired a controlling interest in four surgery centers. The aggregate amount paid for the centers and for settlement of purchase price payable obligations during the six months ended June 30, 2016 and 2015 was approximately $25.7 million and $95.4 million , respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company's revolving credit agreement. The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. During the six months ended June 30, 2016 , the Company disposed of two surgery centers and recognized a net gain from the disposals of $3.3 million in the six months ended June 30, 2016 . The Company did not dispose of any surgery centers during the six months ended June 30, 2015 . Physician Services Activity The Company completed the acquisition of six physician practices in the six months ended June 30, 2016 and four physician practices in the six months ended June 30, 2015 . The aggregate amount paid for the physician practices and for settlement of purchase price payable obligations during the six months ended June 30, 2016 and 2015 was approximately $255.4 million and $100.7 million , respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company's revolving credit agreement. In addition to the cash paid, approximately $15.4 million of consideration for one physician practice was deferred and will be paid in the next two years , $9.7 million of which is reflected in other accrued liabilities and $5.7 million is reflected in other long-term liabilities in the accompanying consolidated balance sheets. As a result of certain acquisitions completed during prior periods, the Company has agreed to pay as additional consideration amounts which are contingent on the acquired entities achieving future performance metrics. As of June 30, 2016 and December 31, 2015 , the Company had accrued $1.0 million and $5.5 million , respectively, as a component of other accrued liabilities in the accompanying consolidated balance sheets, which represents management's estimate of the fair values of the contingent consideration. During the six months ended June 30, 2016 , the Company made a cash payment of $1.9 million for one acquisition and recognized a decrease of $2.6 million associated with the change in fair value of its remaining accrued contingent consideration. As of June 30, 2016 , the Company estimates it may have to pay approximately $1.0 million in future contingent payments for one acquisition made prior to December 31, 2015 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisition over each respective measurement period. The acquisitions completed during the six months ended June 30, 2016 did not contain provisions for contingent consideration. The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the potential remaining payments of contingent consideration is expected to occur within one year. Purchase Price Allocations The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major financial class for both the ambulatory services and physician services acquisitions completed in the six months ended June 30, 2016 , including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): Six Months Ended June 30, 2016 (1) Accounts receivable $ 16,809 Other current assets 1,397 Property and equipment 4,258 Goodwill 209,194 Intangible assets 115,902 Other long-term assets 67 Accounts payable (450 ) Other accrued liabilities (20,331 ) Deferred income taxes (20,706 ) Other long-term liabilities (5,700 ) Long-term debt (128 ) Total fair value 300,312 Less: Fair value attributable to noncontrolling interests 19,199 Acquisition date fair value of total consideration transferred $ 281,113 (1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at June 30, 2016 . During 2016 , no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2015 . The total fair value of acquisitions completed by the Company include amounts allocated to goodwill, which result from the acquisitions' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. Additionally, the Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests associated with acquisitions completed in the last 12 months. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the amortizable intangible assets recognized. The amount allocated to the deferred income tax liability is subject to change as a result of the final allocation of purchase price to amortizable intangibles. The Company expects to finalize the purchase price allocation for its most recent acquisitions as soon as practical. During the three and six months ended June 30, 2016 , the Company incurred approximately $5.1 million and $6.5 million of transaction costs, respectively, and during the three and six months ended June 30, 2015 , the Company incurred approximately $2.0 million and $3.5 million , respectively. The costs incurred during the three months ended June 30, 2016 were primarily associated with the definitive merger agreement with Envision Healthcare Holdings, Inc. signed on June 15, 2016. See Note 2 for additional information. Net revenue and net earnings included in the six months ended June 30, 2016 and 2015 associated with completed acquisitions are as follows (in thousands): Six Months Ended June 30, 2016 2015 Net revenue $ 12,714 $ 48,042 Net earnings $ 2,198 $ 9,101 Less: Net earnings attributable to noncontrolling interests 563 2,353 Net earnings attributable to AmSurg Corp. common shareholders $ 1,635 $ 6,748 The unaudited consolidated pro forma results for the six months ended June 30, 2016 and 2015 , assuming all 2016 acquisitions had been consummated on January 1, 2015 , and all 2015 acquisitions had been consummated on January 1, 2014 are as follows (in thousands, except earnings per share): Six Months Ended June 30, 2016 2015 Net revenue $ 1,558,347 $ 1,488,632 Net earnings 198,383 221,765 Amounts attributable to AmSurg Corp. common shareholders: Net earnings 82,806 68,374 Net earnings per common share: Basic $ 1.53 $ 1.44 Diluted $ 1.52 $ 1.42

Investments in Unconsolidated A

Investments in Unconsolidated Affiliates	6 Months Ended
	Jun. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]
Investments in Unconsolidated Affiliates	Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary. As of June 30, 2016 and December 31, 2015 , the Company recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $179.1 million and $169.2 million , respectively. The Company's net earnings from these investments during the three months ended June 30, 2016 and 2015 were approximately $7.4 million and $4.0 million , respectively, and during the six months ended June 30, 2016 and 2015 were approximately $13.9 million and $6.6 million , respectively. During the six months ended June 30, 2016 , the Company's ambulatory services segment sold a portion of its interest in one surgery center, which resulted in the surgery center being deconsolidated and subsequently accounted for as an equity method investment. During the six months ended June 30, 2015 , the Company's ambulatory services segment entered into one equity method investment. As a result of this investment, the Company contributed its controlling interest in a center and a noncontrolling interest in an entity that owned one ASC prior to the transaction and, after the completion of the transaction, controls the contributed center and the center it previously owned. During the six months ended June 30, 2015 , the Company's physician services segment contributed one site of service into an entity jointly owned by the Company and a health system. There was no deconsolidation activity for the physician services segment during the six months ended June 30, 2016 . As a result of these transactions, the Company recorded in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates, the fair value of the Company's investment in these entities of approximately $1.8 million and $2.3 million during the six months ended June 30, 2016 and 2015 , respectively. In each of these transactions, the gain or loss on deconsolidation was determined based on the difference between the fair value of the Company’s interest, which was based on estimates of the expected future earnings, in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers immediately prior to each transaction. During the three and six months ended June 30, 2016 , the Company recognized a net loss on deconsolidation related to this center in the accompanying consolidated statements of earnings of approximately $0.7 million , respectively. During the three and six months ended June 30, 2015 , the Company recognized a net loss on deconsolidation in the accompanying consolidated statements of earnings of approximately $3.0 million and $3.3 million , respectively.

Prepaid and Other Current Asset

Prepaid and Other Current Assets	6 Months Ended
	Jun. 30, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and Other Current Assets	Prepaid and Other Current Assets The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, 2016 2015 Income taxes receivable $ 16,241 $ 7,908 Prepaid expenses 22,104 18,900 Deferred compensation plan assets 23,530 16,623 Other 12,690 32,340 Total prepaid and other current assets $ 74,565 $ 75,771

Goodwill And Intangible Assets

Goodwill And Intangible Assets	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the six months ended June 30, 2016 are as follows (in thousands): Balance at December 31, 2015 $ 3,970,210 Goodwill acquired, including post acquisition adjustments 207,333 Goodwill disposed, including impact of deconsolidation transactions (2,535 ) Balance at June 30, 2016 $ 4,175,008 As of June 30, 2016 , the ambulatory services segment and the physician services segment each had approximately $2.1 billion of goodwill. During the six months ended June 30, 2016 , goodwill increased $38.4 million for the ambulatory services segment primarily due to the acquisition of four centers, net of one deconsolidation. During the six months ended June 30, 2016 , goodwill increased by $166.4 million for the physician services segment, primarily due to the acquisition of six physician practices and post-acquisition adjustments associated with acquisitions completed during 2015 . For the six months ended June 30, 2016 and 2015 , respectively, approximately $100.9 million and $107.6 million of goodwill recorded was deductible for tax purposes. Intangible assets at June 30, 2016 and December 31, 2015 consisted of the following (in thousands): June 30, 2016 December 31, 2015 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,494,790 $ (109,444 ) $ 1,385,346 $ 1,379,977 $ (74,490 ) $ 1,305,487 Capitalized software 81,595 (33,500 ) 48,095 71,462 (28,125 ) 43,337 Agreements, contracts and other 12,358 (3,519 ) 8,839 11,267 (2,449 ) 8,818 Total amortizable intangible assets 1,588,743 (146,463 ) 1,442,280 1,462,706 (105,064 ) 1,357,642 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 8,995 — 8,995 Total non-amortizable intangible assets 236,995 — 236,995 236,995 — 236,995 Total intangible assets $ 1,825,738 $ (146,463 ) $ 1,679,275 $ 1,699,701 $ (105,064 ) $ 1,594,637 Amortization of intangible assets for the three months ended June 30, 2016 and 2015 was $21.1 million and $14.7 million , respectively, and $41.5 million and $29.2 million for the six months ended June 30, 2016 and 2015 , respectively. Estimated amortization of intangible assets for the remainder of 2016 and each of the following five years and thereafter is $44.9 million , $88.6 million , $87.4 million , $84.7 million , $82.4 million , $78.0 million and $976.3 million , respectively. The Company expects to recognize amortization of all intangible assets over a weighted average period of 17.9 years with no expected residual values.

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities, Current [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Other Accrued Liabilities The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, 2016 2015 Accrued professional liabilities $ 14,541 $ 14,362 Contingent purchase price payable 1,000 5,509 Current income taxes payable — 7,892 Refunds payable 29,626 48,415 Other 47,404 43,059 Total other accrued liabilities $ 92,571 $ 119,237

Accrued Professional Liabilitie

Accrued Professional Liabilities	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accounts Professional Liabilities	Accrued Professional Liabilities The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer, which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted. At June 30, 2016 and December 31, 2015 , the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands): June 30, 2016 December 31, 2015 Estimated losses under self-insured programs $ 32,652 $ 30,748 Incurred but not reported losses 35,955 36,166 Total accrued professional liabilities 68,607 66,914 Less estimated losses payable within one year 14,541 14,362 Total $ 54,066 $ 52,552 The changes to the Company's estimated losses under self-insured programs as of June 30, 2016 were as follows (in thousands): Balance at December 31, 2015 $ 66,914 Assumed liabilities through acquisitions 1,862 Provision related to current period reserves 10,037 Payments for current period reserves (39 ) Benefit related to changes in prior period reserves (249 ) Payments for prior period reserves (6,307 ) Other, net including post-acquisition adjustments (3,611 ) Balance at June 30, 2016 $ 68,607

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Long-term Debt Long-term debt at June 30, 2016 and December 31, 2015 consisted of the following (in thousands): June 30, December 31, 2016 2015 Revolving credit agreement $ 400,000 $ 175,000 Term loan 852,600 856,950 5.625% Senior Unsecured Notes due 2020 250,000 250,000 5.625% Senior Unsecured Notes due 2022 1,100,000 1,100,000 Other debt due through 2025 23,920 24,944 Capitalized lease arrangements due through 2026 18,202 18,613 2,644,722 2,425,507 Less current portion 20,772 20,377 Less net deferred financing costs 42,907 47,174 Long-term debt $ 2,581,043 $ 2,357,956 The fair value of fixed rate long-term debt, with a carrying value of $1,391.1 million , was $1,438.2 million at June 30, 2016 . The fair value of variable rate long-term debt approximates its carrying value of $1,253.6 million at June 30, 2016 . With the exception of the Company’s 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes (each defined below), the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market. a. Term Loan and Credit Facility The Company has a credit facility that is comprised of an $870.0 million term loan and a $500.0 million revolving credit facility. On October 21, 2015, the Company exercised the accordion feature of its revolving credit facility and increased the Company's borrowing capacity by $200.0 million to $500.0 million . As of June 30, 2016 , the Company had available $100.0 million under the revolving credit facility. The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00% , with a LIBOR floor of 0.75% , or a combination thereof ( 3.50% on June 30, 2016 ). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually. The revolving credit facility matures on July 16, 2019 and permits the Company to borrow up to $500.0 million at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00% , or a combination thereof, and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the senior secured credit facility by an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s less than wholly-owned subsidiaries. As of June 30, 2016 , the Company was in compliance with the covenants contained in the term loan and credit facility. b. Senior Unsecured Notes 2020 Senior Unsecured Notes The Company has $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (the 2020 Senior Unsecured Notes). The 2020 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020 . The Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on November 30 of the years indicated below: Period Redemption Price 2015 104.219 % 2016 102.813 % 2017 101.406 % 2018 and thereafter 100.000 % The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2020 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory convertible preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at June 30, 2016 . 2022 Senior Unsecured Notes The Company has $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (the 2022 Senior Unsecured Notes). The 2022 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, through the maturity date of July 15, 2022. Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on July 15 of the years indicated below: Period Redemption Price 2017 104.219 % 2018 102.813 % 2019 101.406 % 2020 and thereafter 100.000 % The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at June 30, 2016 .

Other Long-Term Liabilities

Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2016
Other Long-Term Liabilities [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]	Other Long-Term Liabilities Other long-term liabilities consist of the following (in thousands): June 30, December 31, 2016 2015 Accrued professional liabilities $ 54,066 $ 52,552 Deferred rent 27,330 18,958 Tax-effected unrecognized benefits 3,426 3,426 Other 34,656 21,247 Other long-term liabilities $ 119,478 $ 96,183

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity a. Common Stock During December 2015, the Company issued 5,835,000 shares of its common stock in a public offering, at $80.00 per share, prior to underwriting discounts, commissions, and other related offering expenses of approximately $19.1 million . Proceeds were used to repay a portion of the Company's revolving credit facility, to fund a portion of the acquisitions completed during the three months ended December 31, 2015 and for general corporate purposes. In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vests to cover payroll withholding taxes in accordance with the restricted stock agreements. During the six months ended June 30, 2016 and 2015 , the Company repurchased 77,780 shares and 67,000 shares, respectively, of common stock for approximately $5.7 million and $3.7 million , respectively. b. Preferred Stock The Company has 1,725,000 shares outstanding of its mandatory convertible preferred stock. The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100 , plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount. During each of the six months ended June 30, 2016 and 2015 , the Company's Board of Directors declared two dividends each of $1.3125 per share in cash, or $2.3 million , for the Company’s mandatory convertible preferred stock. As of June 30, 2016 , the dividend declared in May 2016 was funded to the paying agent to be paid to shareholders of record as of June 15, 2016 . c. Stock Incentive Plans In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan (the “2014 Plan”), which was amended in May 2016. The amendment increased the number of shares that may be awarded under the 2014 Plan from 1,200,000 to 3,200,000 . The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At June 30, 2016 , 3,200,000 shares were authorized for grant under the 2014 Plan and 2,396,435 shares were available for future equity grants. Restricted stock granted to outside directors vests on the first anniversary of the date of grant. Restricted stock granted to employees generally vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date. Under Company policy, shares held by outside directors and senior management are subject to certain holding requirements and restrictions. The Company has not issued options subsequent to 2008, and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant. Other information pertaining to share-based activity during the three and six months ended June 30, 2016 and 2015 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Share-based compensation expense $ 7,900 $ 3,883 $ 15,068 $ 7,592 Fair value of shares vested 1,282 1,746 18,243 13,220 Cash received from option exercises 174 334 450 2,080 Tax benefit from exercises of share based awards 129 216 3,734 3,533 As of June 30, 2016 , the Company had total unrecognized compensation cost of approximately $45.6 million related to non-vested awards, which the Company expects to recognize through 2020 and over a weighted average period of 1.2 years. For the three and six months ended June 30, 2016 and 2015 , there were no options that were anti-dilutive. A summary of the status of non-vested restricted shares at June 30, 2016 and changes during the six months ended June 30, 2016 is as follows: Weighted Number Average of Shares Grant Price Non-vested shares at December 31, 2015 734,101 $ 44.73 Shares granted 586,791 74.00 Shares vested (249,421 ) 38.61 Shares forfeited (5,407 ) 55.40 Non-vested shares at June 30, 2016 1,066,064 $ 62.22 In addition to the non-vested restricted shares, during the six months ended June 30, 2016 , the Company granted 74,752 performance-based restricted stock units (RSUs) to certain of its officers and physician employees. The weighted average fair value of the Company's common stock on the grant date of these RSUs was $74.09 . Subject to achieving applicable performance thresholds, the RSUs will vest ratably over a three year period from the grant date. The conversion of the RSUs to restricted stock is contingent on the Company’s achievement of a specified one -year financial performance goal for the year ended December 31, 2016 and, if achieved, would occur during the first quarter of 2017. If the financial performance goal is not achieved, the RSUs will be forfeited. The number of RSUs that will ultimately be received by the holders range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At June 30, 2016 , the Company believes the RSUs will vest at approximately 150% . A summary of stock option activity for the six months ended June 30, 2016 is summarized as follows: Weighted Weighted Average Average Remaining Number Exercise Contractual of Shares Price Term (in years) Outstanding at December 31, 2015 33,751 $ 22.98 1.1 Options exercised with total intrinsic value of $1.0 million (19,718 ) 22.84 Options terminated (4,200 ) 21.07 Outstanding, Vested and Exercisable at June 30, 2016 with an aggregate intrinsic value of $0.5 million 9,833 $ 24.09 0.5 The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at June 30, 2016 exercised their options at the Company’s closing stock price on June 30, 2016 . d. Earnings per Share Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive. For the three and six months ended June 30, 2015 , approximately 3.1 million common share equivalents related to the mandatory convertible preferred stock were anti-dilutive and therefore are excluded from the dilutive weighted average number of shares outstanding. The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, Earnings Shares Per Share Earnings Shares Per Share (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount 2016: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 43,805 53,739 $ 0.82 $ 72,404 53,702 $ 1.35 Preferred stock dividends 2,264 — 4,528 — Effect of dilutive securities, options and non-vested shares — 3,588 — 3,527 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 46,069 57,327 $ 0.80 $ 76,932 57,229 $ 1.34 2015: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 31,411 47,678 $ 0.66 $ 50,185 47,625 $ 1.05 Effect of dilutive securities, options and non-vested shares — 421 — 377 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 31,411 48,099 $ 0.65 $ 50,185 48,002 $ 1.05

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statements of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months. The Company and its subsidiaries file U.S. federal and various state tax returns. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012 . During the six months ended June 30, 2016 and 2015 the Company had net income tax payments of $45.7 million and $7.8 million , respectively. The increase in net payments made is primarily due to lower taxes paid in the six months ended June 30, 2015 due to the tax benefit resulting from significant transaction costs incurred in association with the Sheridan acquisition completed during 2014.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies Litigation From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows. Insurance Programs Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer, which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third-party insurers for its surgery centers and certain of its owned practices and employed physicians. The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value. The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Redeemable Noncontrolling Interests Certain of the Company’s wholly-owned subsidiaries are responsible for all debts incurred but unpaid by the Company's less than wholly-owned partnerships as these subsidiaries are the general partner. As manager of the operations of these partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions. In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of June 30, 2016 . As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets. Physician Services Operating Lease On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida, which will be utilized by its physician services segment. The Company took possession of the space in the fourth quarter of 2015 and began tenant improvements on approximately 167,000 square feet of space, which it intends to begin to occupy during the third quarter of 2016. In addition, the Company plans to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which it intends to occupy during the first quarter of 2017. Annual rent expense is expected to be approximately $2.9 million . The initial term of this lease agreement expires in February 2029. Merger with Envision Healthcare Holdings, Inc. On June 15, 2016, the Company signed a definitive merger agreement with Envision as previously mentioned in Note 2. If the Company were to terminate the merger agreement, under certain circumstances, it would be required to pay Envision a termination fee of $180.0 million and would be obligated to provide reimbursement for up to $15.0 million of expenses.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting The Company operates in two major lines of business - ambulatory surgery centers and outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services, and emergency medicine. The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer. The following table presents financial information for each reportable segment (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net Revenue: Ambulatory Services $ 319,747 $ 310,991 $ 626,881 $ 594,901 Physician Services 438,752 330,959 856,296 617,494 Total $ 758,499 $ 641,950 $ 1,483,177 $ 1,212,395 Adjusted EBITDA: Ambulatory Services $ 61,746 $ 60,304 $ 115,372 $ 107,612 Physician Services 87,497 67,668 153,971 114,115 Total $ 149,243 $ 127,972 $ 269,343 $ 221,727 Adjusted EBITDA: $ 149,243 $ 127,972 $ 269,343 $ 221,727 Net earnings attributable to noncontrolling interests 57,050 57,072 110,891 104,789 Interest expense, net (31,913 ) (30,182 ) (62,723 ) (60,429 ) Depreciation and amortization (30,054 ) (23,612 ) (59,126 ) (46,430 ) Share-based compensation (7,900 ) (3,883 ) (15,068 ) (7,592 ) Net change in fair value of contingent consideration 2,598 (6,410 ) 2,598 (6,410 ) Transaction costs (5,135 ) (1,982 ) (6,525 ) (3,453 ) Net gain (loss) on disposals and deconsolidations 2,595 (3,035 ) 2,595 (3,258 ) Earnings before income taxes $ 136,484 $ 115,940 $ 241,985 $ 198,944 Acquisition and Capital Expenditures: Ambulatory Services $ 35,031 $ 64,514 $ 43,401 $ 118,610 Physician Services 265,019 22,822 275,330 110,087 Total $ 300,050 $ 87,336 $ 318,731 $ 228,697

Financial Information for the C

Financial Information for the Company and Its Subsidiaries	6 Months Ended
	Jun. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Financial Information for the Company and Its Subsidiaries	Financial Information for the Company and Its Subsidiaries The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis. Condensed Consolidating Balance Sheet - June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 4,591 $ 16,215 $ 53,299 $ — $ 74,105 Restricted cash and marketable securities — — 12,794 — 12,794 Accounts receivable, net — 258,863 116,489 — 375,352 Supplies inventory — — 21,980 — 21,980 Prepaid and other current assets 45,542 24,074 26,261 (21,312 ) 74,565 Total current assets 50,133 299,152 230,823 (21,312 ) 558,796 Property and equipment, net 11,877 27,822 165,223 — 204,922 Investments in and receivables from unconsolidated affiliates 5,219,975 1,807,424 — (6,848,343 ) 179,056 Goodwill — 2,123,067 — 2,051,941 4,175,008 Intangible assets, net 13,037 1,664,313 1,925 — 1,679,275 Other assets 7,186 20,825 20,251 (1,999 ) 46,263 Total assets $ 5,302,208 $ 5,942,603 $ 418,222 $ (4,819,713 ) $ 6,843,320 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ 20 $ 12,052 $ — $ 20,772 Accounts payable 3,073 1,640 29,569 (3,561 ) 30,721 Accrued salaries and benefits 29,533 140,149 17,226 — 186,908 Accrued interest 30,386 — 14 — 30,400 Other accrued liabilities 5,171 69,166 35,985 (17,751 ) 92,571 Total current liabilities 76,863 210,975 94,846 (21,312 ) 361,372 Long-term debt 2,550,996 36 56,065 (26,054 ) 2,581,043 Deferred income taxes 288,503 456,942 — (1,998 ) 743,447 Other long-term liabilities 8,568 76,144 34,766 — 119,478 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 60,886 116,959 177,845 Equity: Total AmSurg Corp. equity 2,377,278 3,967,431 125,450 (4,092,881 ) 2,377,278 Noncontrolling interests – non-redeemable — 2,918 46,209 433,730 482,857 Total equity 2,377,278 3,970,349 171,659 (3,659,151 ) 2,860,135 Total liabilities and equity $ 5,302,208 $ 5,942,603 $ 418,222 $ (4,819,713 ) $ 6,843,320 Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Restricted cash and marketable securities — — 13,506 — 13,506 Accounts receivable, net — 223,434 113,896 — 337,330 Supplies inventory — — 21,406 — 21,406 Prepaid and other current assets 28,739 39,046 16,062 (8,076 ) 75,771 Total current assets 49,176 289,987 223,586 (8,076 ) 554,673 Property and equipment, net 12,515 14,601 162,052 — 189,168 Investments in and receivables from unconsolidated affiliates 4,901,026 1,775,272 — (6,507,128 ) 169,170 Goodwill — 1,956,741 — 2,013,469 3,970,210 Intangible assets, net 12,780 1,579,537 2,320 — 1,594,637 Other assets 4,653 1,717 17,078 (1,998 ) 21,450 Total assets $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 11,677 $ — $ 20,377 Accounts payable 2,816 3,760 29,837 (3,852 ) 32,561 Accrued salaries and benefits 31,510 158,705 12,322 — 202,537 Accrued interest 30,463 — 17 — 30,480 Other accrued liabilities 13,962 76,590 32,909 (4,224 ) 119,237 Total current liabilities 87,451 239,055 86,762 (8,076 ) 405,192 Long-term debt 2,326,103 — 55,249 (23,396 ) 2,357,956 Deferred income taxes 268,573 432,923 — (1,998 ) 699,498 Other long-term liabilities 4,560 71,509 20,114 — 96,183 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 63,060 112,672 175,732 Equity: Total AmSurg Corp. equity 2,293,463 3,646,211 132,267 (3,778,478 ) 2,293,463 Noncontrolling interests – non-redeemable — — 47,584 423,700 471,284 Total equity 2,293,463 3,646,211 179,851 (3,354,778 ) 2,764,747 Total liabilities and equity $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308 Condensed Consolidating Statement of Operations - For the Three Months Ended June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 7,700 $ 437,042 $ 324,047 $ (10,290 ) $ 758,499 Operating expenses: Salaries and benefits 22,246 305,173 76,727 (135 ) 404,011 Supply cost — 1,145 48,578 (20 ) 49,703 Other operating expenses 6,034 44,213 71,033 (10,135 ) 111,145 Transaction costs 2,099 3,036 — — 5,135 Depreciation and amortization 1,103 21,192 7,759 — 30,054 Total operating expenses 31,482 374,759 204,097 (10,290 ) 600,048 Net gain (loss) on disposals and deconsolidations — 2,857 (262 ) — 2,595 Equity in earnings of unconsolidated affiliates 87,700 68,939 — (149,288 ) 7,351 Operating income 63,918 134,079 119,688 (149,288 ) 168,397 Interest expense (income), net (4,215 ) 35,528 600 — 31,913 Earnings before income taxes 68,133 98,551 119,088 (149,288 ) 136,484 Income tax expense 22,064 10,858 443 — 33,365 Net earnings 46,069 87,693 118,645 (149,288 ) 103,119 Less net earnings (loss) attributable to noncontrolling interests — (7 ) 57,057 — 57,050 Net earnings attributable to AmSurg Corp. shareholders 46,069 87,700 61,588 (149,288 ) 46,069 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 43,805 $ 87,700 $ 61,588 $ (149,288 ) $ 43,805 Condensed Consolidating Statement of Operations - For the Six Months Ended June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 16,244 $ 852,872 $ 634,659 $ (20,598 ) $ 1,483,177 Operating expenses: Salaries and benefits 46,341 614,753 153,024 (268 ) 813,850 Supply cost — 2,152 94,547 (33 ) 96,666 Other operating expenses 13,652 87,552 137,920 (20,297 ) 218,827 Transaction costs 2,276 4,249 — — 6,525 Depreciation and amortization 2,175 41,528 15,423 — 59,126 Total operating expenses 64,444 750,234 400,914 (20,598 ) 1,194,994 Net gain (loss) on disposals and deconsolidations — 2,857 (262 ) — 2,595 Equity in earnings of unconsolidated affiliates 156,742 134,375 — (277,187 ) 13,930 Operating income 108,542 239,870 233,483 (277,187 ) 304,708 Interest expense (income), net (7,034 ) 68,504 1,253 — 62,723 Earnings before income taxes 115,576 171,366 232,230 (277,187 ) 241,985 Income tax expense 38,644 14,632 886 — 54,162 Net earnings 76,932 156,734 231,344 (277,187 ) 187,823 Less net earnings (loss) attributable to noncontrolling interests — (7 ) 110,898 — 110,891 Net earnings attributable to AmSurg Corp. shareholders 76,932 156,741 120,446 (277,187 ) 76,932 Preferred stock dividends (4,528 ) — — — (4,528 ) Net earnings attributable to AmSurg Corp. common shareholders $ 72,404 $ 156,741 $ 120,446 $ (277,187 ) $ 72,404 Condensed Consolidating Statement of Operations - For the Three Months Ended June 30, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 7,079 $ 329,579 $ 314,780 $ (9,488 ) $ 641,950 Operating expenses: Salaries and benefits 15,511 228,618 76,391 (124 ) 320,396 Supply cost — 489 45,335 (34 ) 45,790 Other operating expenses 5,783 42,099 66,450 (9,330 ) 105,002 Transaction costs 324 1,658 — — 1,982 Depreciation and amortization 1,056 14,617 7,939 — 23,612 Total operating expenses 22,674 287,481 196,115 (9,488 ) 496,782 Net gain (loss) on disposals and deconsolidations — (3,035 ) — — (3,035 ) Equity in earnings of unconsolidated affiliates 76,931 64,513 — (137,455 ) 3,989 Operating income 61,336 103,576 118,665 (137,455 ) 146,122 Interest expense, net 11,978 17,624 580 — 30,182 Earnings before income taxes 49,358 85,952 118,085 (137,455 ) 115,940 Income tax expense 15,683 9,021 489 — 25,193 Net earnings 33,675 76,931 117,596 (137,455 ) 90,747 Less net earnings attributable to noncontrolling interests — — 57,072 — 57,072 Net earnings attributable to AmSurg Corp. shareholders 33,675 76,931 60,524 (137,455 ) 33,675 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 31,411 $ 76,931 $ 60,524 $ (137,455 ) $ 31,411 Condensed Consolidating Statement of Operations - For the Six Months Ended June 30, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 14,170 $ 615,158 $ 601,409 $ (18,342 ) $ 1,212,395 Operating expenses: Salaries and benefits 33,154 440,219 149,454 (252 ) 622,575 Supply cost — 885 87,523 (34 ) 88,374 Other operating expenses 12,417 71,710 129,501 (18,056 ) 195,572 Transaction costs 592 2,861 — — 3,453 Depreciation and amortization 1,890 28,924 15,616 — 46,430 Total operating expenses 48,053 544,599 382,094 (18,342 ) 956,404 Net gain (loss) on disposals and deconsolidations (188 ) (3,223 ) (35 ) 188 (3,258 ) Equity in earnings of unconsolidated affiliates 137,318 119,096 — (249,774 ) 6,640 Operating income 103,247 186,432 219,280 (249,586 ) 259,373 Interest expense, net 23,864 35,378 1,187 — 60,429 Earnings before income taxes 79,383 151,054 218,093 (249,586 ) 198,944 Income tax expense 24,670 13,924 848 — 39,442 Net earnings 54,713 137,130 217,245 (249,586 ) 159,502 Less net earnings attributable to noncontrolling interests — — 104,789 — 104,789 Net earnings attributable to AmSurg Corp. shareholders 54,713 137,130 112,456 (249,586 ) 54,713 Preferred stock dividends (4,528 ) — — — (4,528 ) Net earnings attributable to AmSurg Corp. common shareholders $ 50,185 $ 137,130 $ 112,456 $ (249,586 ) $ 50,185 Condensed Consolidating Statement of Cash Flows - For the Six Months Ended June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 39,294 $ 131,227 $ 255,297 $ (230,713 ) $ 195,105 Cash flows from investing activities: Acquisitions and related expenses (265,258 ) (284,010 ) — 268,155 (281,113 ) Acquisition of property and equipment (1,676 ) (19,916 ) (16,026 ) — (37,618 ) Proceeds from sale of interests in surgery centers — 25 — — 25 Purchases of marketable securities — — (498 ) — (498 ) Maturities of marketable securities — — 2,738 — 2,738 Other — (4,057 ) (4,692 ) — (8,749 ) Net cash flows used in investing activities (266,934 ) (307,958 ) (18,478 ) 268,155 (325,215 ) Cash flows from financing activities: Proceeds from long-term borrowings 313,000 — 4,151 — 317,151 Repayment on long-term borrowings (92,350 ) (9 ) (6,404 ) — (98,763 ) Distributions to owners, including noncontrolling interests — (102,330 ) (243,972 ) 230,713 (115,589 ) Capital contributions — 265,258 — (265,258 ) — Changes in intercompany balances with affiliates, net (2,657 ) — 2,657 — — Other, net (6,199 ) 2,520 1,332 (2,897 ) (5,244 ) Net cash flows provided by (used in) financing activities 211,794 165,439 (242,236 ) (37,442 ) 97,555 Net decrease in cash and cash equivalents (15,846 ) (11,292 ) (5,417 ) — (32,555 ) Cash and cash equivalents, beginning of period 20,437 27,507 58,716 — 106,660 Cash and cash equivalents, end of period $ 4,591 $ 16,215 $ 53,299 $ — $ 74,105 Condensed Consolidating Statement of Cash Flows - For the Six Months Ended June 30, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by (used in) operating activities $ (27,553 ) $ 172,907 $ 232,423 $ (126,382 ) $ 251,395 Cash flows from investing activities: Acquisitions and related expenses (51,852 ) (197,718 ) — 53,538 (196,032 ) Acquisition of property and equipment (4,490 ) (9,424 ) (18,751 ) — (32,665 ) Purchases of marketable securities — — (1,245 ) — (1,245 ) Maturities of marketable securities — — 2,988 — 2,988 Other — (1,441 ) (546 ) — (1,987 ) Net cash flows used in investing activities (56,342 ) (208,583 ) (17,554 ) 53,538 (228,941 ) Cash flows from financing activities: Proceeds from long-term borrowings — — 7,795 — 7,795 Repayment on long-term borrowings (4,350 ) — (5,938 ) — (10,288 ) Distributions to owners, including noncontrolling interests — (15,108 ) (212,307 ) 126,382 (101,033 ) Capital contributions — 51,852 — (51,852 ) — Changes in intercompany balances with affiliates, net 444 — (444 ) — — Other financing activities, net (2,892 ) 2,573 1,287 (1,686 ) (718 ) Net cash flows provided by (used in) financing activities (6,798 ) 39,317 (209,607 ) 72,844 (104,244 ) Net increase (decrease) in cash and cash equivalents (90,693 ) 3,641 5,262 — (81,790 ) Cash and cash equivalents, beginning of period 134,351 23,471 50,257 — 208,079 Cash and cash equivalents, end of period $ 43,658 $ 27,112 $ 55,519 $ — $ 126,289

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all normal recurring adjustments, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in AmSurg Corp.'s (Company) Annual Report on Form 10-K for the fiscal year ended December 31, 2015 . Ambulatory Services The Company, through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers). All LLCs and LPs are referred to herein as “partnerships” and “partners,” respectively. The Company has variable interests in the partnerships through its equity ownership interests. Each partnership is considered a variable interest entity (VIE) due to its structure as a limited partnership or functional equivalent under Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2015-02 “Consolidations (Topic 810) - Amendments to the Consolidation Analysis,” which was adopted effective January 1, 2016. For those partnerships in which the Company’s ownership interest is 51% or greater, the Company is considered the primary beneficiary. The Company is the primary beneficiary due to 1) ownership interest, operating agreements allowing the Company to govern the day-to-day activities, and the Company’s position as the managing member or general partner and 2) the Company's obligation to absorb losses or the right to receive returns proportionate to its equity interest in the partnerships. For the 24 partnerships in which the Company’s ownership interest is less than 51%, the Company is not deemed the primary beneficiary and therefore those partnerships are not consolidated with the exception of 2 partnerships which are consolidated because the Company holds substantive participation rights and has the obligation to absorb losses or right to receive returns proportionate to its equity interest in the partnerships. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated partnerships. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net earnings attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions when there is no change in control; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis. Physician Services The Company, through its wholly-owned subsidiary Sheridan Healthcare, is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. The Company focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, the Company is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. The Company also provides physician services and manages office-based practices in the areas of pain management, gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which the Company has management arrangements. The Company's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned subsidiaries. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “ Consolidations. ”
Restricted Cash	Restricted Cash and Marketable Securities As of June 30, 2016 and December 31, 2015 , the Company had $29.9 million and $27.4 million , respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets the majority of which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $17.1 million and $13.9 million as of June 30, 2016 and December 31, 2015 , respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of June 30, 2016 and December 31, 2015 , the Company had $0.5 million and $2.7 million , respectively, included in restricted cash and marketable securities, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.
Reclassifications	Reclassifications Certain prior year amounts in the accompanying consolidated financial statements have been reclassified to reflect the adoption of ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” as discussed further under “Recent Accounting Pronouncements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. In 2016, the FASB issued the following ASUs to provide entities further clarity on the application of ASU 2014-09: • ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” • ASU 2016-10 “Identifying Performance Obligations and Licensing” • ASU 2016-12 “Narrow-Scope Improvements and Practical Expedients” The guidance in ASU 2014-09 and the subsequently related ASUs will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance made amendments to the consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities are considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company adopted this standard effective January 1, 2016 and applied the adoption retrospectively. The adoption of the standard did not result in a change of consolidated subsidiaries nor did it result in any impact to the Company's consolidated financial position, results of operations or cash flows as of and for the three months ended March 31, 2016 or for any previous period. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.” ASU 2015-03 amended current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporated into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards were effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2016 and accordingly, reclassified $47.2 million of deferred debt issuance costs from intangible assets, net to a reduction in long-term debt at December 31, 2015, in the accompanying balance sheets (see reclassification above). In February 2016, the FASB issued ASU No. 2016-02, “Leases” which amends existing accounting standards for lease accounting, including requiring lessees to recognize most leases on the balance sheet and making changes to lessor accounting. The standard is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The new standard requires a modified retrospective application for all leases existing at, or entered into, after the date of initial application, with an option to use certain transition relief. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” which will change how companies account for certain aspects of share-based payments to employees by requiring companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows.
Revenue Recognition	Ambulatory Services Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor. Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During each of the six months ended June 30, 2016 and 2015 , the Company derived approximately 26% of its ambulatory services net revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Physician Services Physician services revenues primarily consist of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors. The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections. The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).
Accounts Receivable	The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts analysis for its physician services segment quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous twelve month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates, if any, are charged or credited to the consolidated statements of operations in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third-party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows. Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statements of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statements of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statements of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent.
Acquisitions	The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.
Investments in Unconsolidated Affiliates	Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
Earnings per Share	Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.
Income Taxes	The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statements of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.
Insurance Programs	Insurance Programs Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer, which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third-party insurers for its surgery centers and certain of its owned practices and employed physicians. The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.
Segments	The Company operates in two major lines of business - ambulatory surgery centers and outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services, and emergency medicine. The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncement Impact	The impact of the reclassification made to prior period balance sheet is presented below (in thousands). December 31, 2015 Consolidated Balance Sheet: Previously reported Reclassification Revised Intangible assets, net $ 1,641,811 $ (47,174 ) $ 1,594,637 Long-term debt $ 2,405,130 $ (47,174 ) $ 2,357,956

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2016
Revenue Recognition [Abstract]
Schedule of Revenue and Fees by Segment and Major Payors	Net revenue for the physician services segment consists of the following major payors (dollars in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Medicare $ 61,775 14 % $ 45,967 14 % $ 120,549 14 % $ 87,296 14 % Medicaid 30,698 7 19,298 6 61,523 7 37,878 6 Commercial and managed care 337,553 77 254,481 77 661,724 77 474,599 77 Self-pay 71,648 16 45,298 14 133,365 16 88,569 14 Net fee for service revenue 501,674 114 365,044 110 977,161 114 688,342 111 Contract and other revenue 38,411 9 31,698 10 74,076 9 62,687 10 Provision for uncollectibles (101,333 ) (23 ) (65,783 ) (20 ) (194,941 ) (23 ) (133,535 ) (22 ) Net revenue for physician services $ 438,752 100 % $ 330,959 100 % $ 856,296 100 % $ 617,494 100 %

Acquisitions and Disposals (Tab

Acquisitions and Disposals (Tables)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major financial class for both the ambulatory services and physician services acquisitions completed in the six months ended June 30, 2016 , including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): Six Months Ended June 30, 2016 (1) Accounts receivable $ 16,809 Other current assets 1,397 Property and equipment 4,258 Goodwill 209,194 Intangible assets 115,902 Other long-term assets 67 Accounts payable (450 ) Other accrued liabilities (20,331 ) Deferred income taxes (20,706 ) Other long-term liabilities (5,700 ) Long-term debt (128 ) Total fair value 300,312 Less: Fair value attributable to noncontrolling interests 19,199 Acquisition date fair value of total consideration transferred $ 281,113 (1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at June 30, 2016
Revenues And Net Earnings Associated With Acquisitions	Net revenue and net earnings included in the six months ended June 30, 2016 and 2015 associated with completed acquisitions are as follows (in thousands): Six Months Ended June 30, 2016 2015 Net revenue $ 12,714 $ 48,042 Net earnings $ 2,198 $ 9,101 Less: Net earnings attributable to noncontrolling interests 563 2,353 Net earnings attributable to AmSurg Corp. common shareholders $ 1,635 $ 6,748
Consolidated Pro Forma Results Of Acquisition	The unaudited consolidated pro forma results for the six months ended June 30, 2016 and 2015 , assuming all 2016 acquisitions had been consummated on January 1, 2015 , and all 2015 acquisitions had been consummated on January 1, 2014 are as follows (in thousands, except earnings per share): Six Months Ended June 30, 2016 2015 Net revenue $ 1,558,347 $ 1,488,632 Net earnings 198,383 221,765 Amounts attributable to AmSurg Corp. common shareholders: Net earnings 82,806 68,374 Net earnings per common share: Basic $ 1.53 $ 1.44 Diluted $ 1.52 $ 1.42

Prepaid and Other Current Ass28

Prepaid and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid and Other Current Assets	The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, 2016 2015 Income taxes receivable $ 16,241 $ 7,908 Prepaid expenses 22,104 18,900 Deferred compensation plan assets 23,530 16,623 Other 12,690 32,340 Total prepaid and other current assets $ 74,565 $ 75,771

Goodwill And Intangible Assets

Goodwill And Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Changes In Carrying Amount Of Goodwill	The changes in the carrying amount of goodwill for the six months ended June 30, 2016 are as follows (in thousands): Balance at December 31, 2015 $ 3,970,210 Goodwill acquired, including post acquisition adjustments 207,333 Goodwill disposed, including impact of deconsolidation transactions (2,535 ) Balance at June 30, 2016 $ 4,175,008
Schedule of Finite-Lived Intangible Assets	Intangible assets at June 30, 2016 and December 31, 2015 consisted of the following (in thousands): June 30, 2016 December 31, 2015 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,494,790 $ (109,444 ) $ 1,385,346 $ 1,379,977 $ (74,490 ) $ 1,305,487 Capitalized software 81,595 (33,500 ) 48,095 71,462 (28,125 ) 43,337 Agreements, contracts and other 12,358 (3,519 ) 8,839 11,267 (2,449 ) 8,818 Total amortizable intangible assets 1,588,743 (146,463 ) 1,442,280 1,462,706 (105,064 ) 1,357,642 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 8,995 — 8,995 Total non-amortizable intangible assets 236,995 — 236,995 236,995 — 236,995 Total intangible assets $ 1,825,738 $ (146,463 ) $ 1,679,275 $ 1,699,701 $ (105,064 ) $ 1,594,637

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities, Current [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, 2016 2015 Accrued professional liabilities $ 14,541 $ 14,362 Contingent purchase price payable 1,000 5,509 Current income taxes payable — 7,892 Refunds payable 29,626 48,415 Other 47,404 43,059 Total other accrued liabilities $ 92,571 $ 119,237

Accrued Professional Liabilit31

Accrued Professional Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Professional Liabilities	At June 30, 2016 and December 31, 2015 , the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands): June 30, 2016 December 31, 2015 Estimated losses under self-insured programs $ 32,652 $ 30,748 Incurred but not reported losses 35,955 36,166 Total accrued professional liabilities 68,607 66,914 Less estimated losses payable within one year 14,541 14,362 Total $ 54,066 $ 52,552
Schedule of Self Insurance Reserve Roll Forward	The changes to the Company's estimated losses under self-insured programs as of June 30, 2016 were as follows (in thousands): Balance at December 31, 2015 $ 66,914 Assumed liabilities through acquisitions 1,862 Provision related to current period reserves 10,037 Payments for current period reserves (39 ) Benefit related to changes in prior period reserves (249 ) Payments for prior period reserves (6,307 ) Other, net including post-acquisition adjustments (3,611 ) Balance at June 30, 2016 $ 68,607

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Components Of Long-Term Debt	Long-term debt at June 30, 2016 and December 31, 2015 consisted of the following (in thousands): June 30, December 31, 2016 2015 Revolving credit agreement $ 400,000 $ 175,000 Term loan 852,600 856,950 5.625% Senior Unsecured Notes due 2020 250,000 250,000 5.625% Senior Unsecured Notes due 2022 1,100,000 1,100,000 Other debt due through 2025 23,920 24,944 Capitalized lease arrangements due through 2026 18,202 18,613 2,644,722 2,425,507 Less current portion 20,772 20,377 Less net deferred financing costs 42,907 47,174 Long-term debt $ 2,581,043 $ 2,357,956
Redemption Price Percentage	The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on November 30 of the years indicated below: Period Redemption Price 2015 104.219 % 2016 102.813 % 2017 101.406 % 2018 and thereafter 100.000 % The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on July 15 of the years indicated below: Period Redemption Price 2017 104.219 % 2018 102.813 % 2019 101.406 % 2020 and thereafter 100.000 %

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Other Long-Term Liabilities [Abstract]
Other Noncurrent Liabilities	Other long-term liabilities consist of the following (in thousands): June 30, December 31, 2016 2015 Accrued professional liabilities $ 54,066 $ 52,552 Deferred rent 27,330 18,958 Tax-effected unrecognized benefits 3,426 3,426 Other 34,656 21,247 Other long-term liabilities $ 119,478 $ 96,183

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Share-Based Activity	Other information pertaining to share-based activity during the three and six months ended June 30, 2016 and 2015 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Share-based compensation expense $ 7,900 $ 3,883 $ 15,068 $ 7,592 Fair value of shares vested 1,282 1,746 18,243 13,220 Cash received from option exercises 174 334 450 2,080 Tax benefit from exercises of share based awards 129 216 3,734 3,533
Schedule Of Changes In Non-Vested Restricted Shares	A summary of the status of non-vested restricted shares at June 30, 2016 and changes during the six months ended June 30, 2016 is as follows: Weighted Number Average of Shares Grant Price Non-vested shares at December 31, 2015 734,101 $ 44.73 Shares granted 586,791 74.00 Shares vested (249,421 ) 38.61 Shares forfeited (5,407 ) 55.40 Non-vested shares at June 30, 2016 1,066,064 $ 62.22
Schedule Of Stock Option Activity	A summary of stock option activity for the six months ended June 30, 2016 is summarized as follows: Weighted Weighted Average Average Remaining Number Exercise Contractual of Shares Price Term (in years) Outstanding at December 31, 2015 33,751 $ 22.98 1.1 Options exercised with total intrinsic value of $1.0 million (19,718 ) 22.84 Options terminated (4,200 ) 21.07 Outstanding, Vested and Exercisable at June 30, 2016 with an aggregate intrinsic value of $0.5 million 9,833 $ 24.09 0.5
Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share	The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, Earnings Shares Per Share Earnings Shares Per Share (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount 2016: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 43,805 53,739 $ 0.82 $ 72,404 53,702 $ 1.35 Preferred stock dividends 2,264 — 4,528 — Effect of dilutive securities, options and non-vested shares — 3,588 — 3,527 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 46,069 57,327 $ 0.80 $ 76,932 57,229 $ 1.34 2015: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 31,411 47,678 $ 0.66 $ 50,185 47,625 $ 1.05 Effect of dilutive securities, options and non-vested shares — 421 — 377 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 31,411 48,099 $ 0.65 $ 50,185 48,002 $ 1.05

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents financial information for each reportable segment (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net Revenue: Ambulatory Services $ 319,747 $ 310,991 $ 626,881 $ 594,901 Physician Services 438,752 330,959 856,296 617,494 Total $ 758,499 $ 641,950 $ 1,483,177 $ 1,212,395 Adjusted EBITDA: Ambulatory Services $ 61,746 $ 60,304 $ 115,372 $ 107,612 Physician Services 87,497 67,668 153,971 114,115 Total $ 149,243 $ 127,972 $ 269,343 $ 221,727 Adjusted EBITDA: $ 149,243 $ 127,972 $ 269,343 $ 221,727 Net earnings attributable to noncontrolling interests 57,050 57,072 110,891 104,789 Interest expense, net (31,913 ) (30,182 ) (62,723 ) (60,429 ) Depreciation and amortization (30,054 ) (23,612 ) (59,126 ) (46,430 ) Share-based compensation (7,900 ) (3,883 ) (15,068 ) (7,592 ) Net change in fair value of contingent consideration 2,598 (6,410 ) 2,598 (6,410 ) Transaction costs (5,135 ) (1,982 ) (6,525 ) (3,453 ) Net gain (loss) on disposals and deconsolidations 2,595 (3,035 ) 2,595 (3,258 ) Earnings before income taxes $ 136,484 $ 115,940 $ 241,985 $ 198,944 Acquisition and Capital Expenditures: Ambulatory Services $ 35,031 $ 64,514 $ 43,401 $ 118,610 Physician Services 265,019 22,822 275,330 110,087 Total $ 300,050 $ 87,336 $ 318,731 $ 228,697

Financial Information for the36

Financial Information for the Company and Its Subsidiaries (Tables)	6 Months Ended
	Jun. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet - June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 4,591 $ 16,215 $ 53,299 $ — $ 74,105 Restricted cash and marketable securities — — 12,794 — 12,794 Accounts receivable, net — 258,863 116,489 — 375,352 Supplies inventory — — 21,980 — 21,980 Prepaid and other current assets 45,542 24,074 26,261 (21,312 ) 74,565 Total current assets 50,133 299,152 230,823 (21,312 ) 558,796 Property and equipment, net 11,877 27,822 165,223 — 204,922 Investments in and receivables from unconsolidated affiliates 5,219,975 1,807,424 — (6,848,343 ) 179,056 Goodwill — 2,123,067 — 2,051,941 4,175,008 Intangible assets, net 13,037 1,664,313 1,925 — 1,679,275 Other assets 7,186 20,825 20,251 (1,999 ) 46,263 Total assets $ 5,302,208 $ 5,942,603 $ 418,222 $ (4,819,713 ) $ 6,843,320 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ 20 $ 12,052 $ — $ 20,772 Accounts payable 3,073 1,640 29,569 (3,561 ) 30,721 Accrued salaries and benefits 29,533 140,149 17,226 — 186,908 Accrued interest 30,386 — 14 — 30,400 Other accrued liabilities 5,171 69,166 35,985 (17,751 ) 92,571 Total current liabilities 76,863 210,975 94,846 (21,312 ) 361,372 Long-term debt 2,550,996 36 56,065 (26,054 ) 2,581,043 Deferred income taxes 288,503 456,942 — (1,998 ) 743,447 Other long-term liabilities 8,568 76,144 34,766 — 119,478 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 60,886 116,959 177,845 Equity: Total AmSurg Corp. equity 2,377,278 3,967,431 125,450 (4,092,881 ) 2,377,278 Noncontrolling interests – non-redeemable — 2,918 46,209 433,730 482,857 Total equity 2,377,278 3,970,349 171,659 (3,659,151 ) 2,860,135 Total liabilities and equity $ 5,302,208 $ 5,942,603 $ 418,222 $ (4,819,713 ) $ 6,843,320 Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Restricted cash and marketable securities — — 13,506 — 13,506 Accounts receivable, net — 223,434 113,896 — 337,330 Supplies inventory — — 21,406 — 21,406 Prepaid and other current assets 28,739 39,046 16,062 (8,076 ) 75,771 Total current assets 49,176 289,987 223,586 (8,076 ) 554,673 Property and equipment, net 12,515 14,601 162,052 — 189,168 Investments in and receivables from unconsolidated affiliates 4,901,026 1,775,272 — (6,507,128 ) 169,170 Goodwill — 1,956,741 — 2,013,469 3,970,210 Intangible assets, net 12,780 1,579,537 2,320 — 1,594,637 Other assets 4,653 1,717 17,078 (1,998 ) 21,450 Total assets $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 11,677 $ — $ 20,377 Accounts payable 2,816 3,760 29,837 (3,852 ) 32,561 Accrued salaries and benefits 31,510 158,705 12,322 — 202,537 Accrued interest 30,463 — 17 — 30,480 Other accrued liabilities 13,962 76,590 32,909 (4,224 ) 119,237 Total current liabilities 87,451 239,055 86,762 (8,076 ) 405,192 Long-term debt 2,326,103 — 55,249 (23,396 ) 2,357,956 Deferred income taxes 268,573 432,923 — (1,998 ) 699,498 Other long-term liabilities 4,560 71,509 20,114 — 96,183 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 63,060 112,672 175,732 Equity: Total AmSurg Corp. equity 2,293,463 3,646,211 132,267 (3,778,478 ) 2,293,463 Noncontrolling interests – non-redeemable — — 47,584 423,700 471,284 Total equity 2,293,463 3,646,211 179,851 (3,354,778 ) 2,764,747 Total liabilities and equity $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308
Condensed Consolidating Statement of Operations	Condensed Consolidating Statement of Operations - For the Three Months Ended June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 7,700 $ 437,042 $ 324,047 $ (10,290 ) $ 758,499 Operating expenses: Salaries and benefits 22,246 305,173 76,727 (135 ) 404,011 Supply cost — 1,145 48,578 (20 ) 49,703 Other operating expenses 6,034 44,213 71,033 (10,135 ) 111,145 Transaction costs 2,099 3,036 — — 5,135 Depreciation and amortization 1,103 21,192 7,759 — 30,054 Total operating expenses 31,482 374,759 204,097 (10,290 ) 600,048 Net gain (loss) on disposals and deconsolidations — 2,857 (262 ) — 2,595 Equity in earnings of unconsolidated affiliates 87,700 68,939 — (149,288 ) 7,351 Operating income 63,918 134,079 119,688 (149,288 ) 168,397 Interest expense (income), net (4,215 ) 35,528 600 — 31,913 Earnings before income taxes 68,133 98,551 119,088 (149,288 ) 136,484 Income tax expense 22,064 10,858 443 — 33,365 Net earnings 46,069 87,693 118,645 (149,288 ) 103,119 Less net earnings (loss) attributable to noncontrolling interests — (7 ) 57,057 — 57,050 Net earnings attributable to AmSurg Corp. shareholders 46,069 87,700 61,588 (149,288 ) 46,069 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 43,805 $ 87,700 $ 61,588 $ (149,288 ) $ 43,805 Condensed Consolidating Statement of Operations - For the Six Months Ended June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 16,244 $ 852,872 $ 634,659 $ (20,598 ) $ 1,483,177 Operating expenses: Salaries and benefits 46,341 614,753 153,024 (268 ) 813,850 Supply cost — 2,152 94,547 (33 ) 96,666 Other operating expenses 13,652 87,552 137,920 (20,297 ) 218,827 Transaction costs 2,276 4,249 — — 6,525 Depreciation and amortization 2,175 41,528 15,423 — 59,126 Total operating expenses 64,444 750,234 400,914 (20,598 ) 1,194,994 Net gain (loss) on disposals and deconsolidations — 2,857 (262 ) — 2,595 Equity in earnings of unconsolidated affiliates 156,742 134,375 — (277,187 ) 13,930 Operating income 108,542 239,870 233,483 (277,187 ) 304,708 Interest expense (income), net (7,034 ) 68,504 1,253 — 62,723 Earnings before income taxes 115,576 171,366 232,230 (277,187 ) 241,985 Income tax expense 38,644 14,632 886 — 54,162 Net earnings 76,932 156,734 231,344 (277,187 ) 187,823 Less net earnings (loss) attributable to noncontrolling interests — (7 ) 110,898 — 110,891 Net earnings attributable to AmSurg Corp. shareholders 76,932 156,741 120,446 (277,187 ) 76,932 Preferred stock dividends (4,528 ) — — — (4,528 ) Net earnings attributable to AmSurg Corp. common shareholders $ 72,404 $ 156,741 $ 120,446 $ (277,187 ) $ 72,404 Condensed Consolidating Statement of Operations - For the Three Months Ended June 30, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 7,079 $ 329,579 $ 314,780 $ (9,488 ) $ 641,950 Operating expenses: Salaries and benefits 15,511 228,618 76,391 (124 ) 320,396 Supply cost — 489 45,335 (34 ) 45,790 Other operating expenses 5,783 42,099 66,450 (9,330 ) 105,002 Transaction costs 324 1,658 — — 1,982 Depreciation and amortization 1,056 14,617 7,939 — 23,612 Total operating expenses 22,674 287,481 196,115 (9,488 ) 496,782 Net gain (loss) on disposals and deconsolidations — (3,035 ) — — (3,035 ) Equity in earnings of unconsolidated affiliates 76,931 64,513 — (137,455 ) 3,989 Operating income 61,336 103,576 118,665 (137,455 ) 146,122 Interest expense, net 11,978 17,624 580 — 30,182 Earnings before income taxes 49,358 85,952 118,085 (137,455 ) 115,940 Income tax expense 15,683 9,021 489 — 25,193 Net earnings 33,675 76,931 117,596 (137,455 ) 90,747 Less net earnings attributable to noncontrolling interests — — 57,072 — 57,072 Net earnings attributable to AmSurg Corp. shareholders 33,675 76,931 60,524 (137,455 ) 33,675 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 31,411 $ 76,931 $ 60,524 $ (137,455 ) $ 31,411 Condensed Consolidating Statement of Operations - For the Six Months Ended June 30, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 14,170 $ 615,158 $ 601,409 $ (18,342 ) $ 1,212,395 Operating expenses: Salaries and benefits 33,154 440,219 149,454 (252 ) 622,575 Supply cost — 885 87,523 (34 ) 88,374 Other operating expenses 12,417 71,710 129,501 (18,056 ) 195,572 Transaction costs 592 2,861 — — 3,453 Depreciation and amortization 1,890 28,924 15,616 — 46,430 Total operating expenses 48,053 544,599 382,094 (18,342 ) 956,404 Net gain (loss) on disposals and deconsolidations (188 ) (3,223 ) (35 ) 188 (3,258 ) Equity in earnings of unconsolidated affiliates 137,318 119,096 — (249,774 ) 6,640 Operating income 103,247 186,432 219,280 (249,586 ) 259,373 Interest expense, net 23,864 35,378 1,187 — 60,429 Earnings before income taxes 79,383 151,054 218,093 (249,586 ) 198,944 Income tax expense 24,670 13,924 848 — 39,442 Net earnings 54,713 137,130 217,245 (249,586 ) 159,502 Less net earnings attributable to noncontrolling interests — — 104,789 — 104,789 Net earnings attributable to AmSurg Corp. shareholders 54,713 137,130 112,456 (249,586 ) 54,713 Preferred stock dividends (4,528 ) — — — (4,528 ) Net earnings attributable to AmSurg Corp. common shareholders $ 50,185 $ 137,130 $ 112,456 $ (249,586 ) $ 50,185
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows - For the Six Months Ended June 30, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 39,294 $ 131,227 $ 255,297 $ (230,713 ) $ 195,105 Cash flows from investing activities: Acquisitions and related expenses (265,258 ) (284,010 ) — 268,155 (281,113 ) Acquisition of property and equipment (1,676 ) (19,916 ) (16,026 ) — (37,618 ) Proceeds from sale of interests in surgery centers — 25 — — 25 Purchases of marketable securities — — (498 ) — (498 ) Maturities of marketable securities — — 2,738 — 2,738 Other — (4,057 ) (4,692 ) — (8,749 ) Net cash flows used in investing activities (266,934 ) (307,958 ) (18,478 ) 268,155 (325,215 ) Cash flows from financing activities: Proceeds from long-term borrowings 313,000 — 4,151 — 317,151 Repayment on long-term borrowings (92,350 ) (9 ) (6,404 ) — (98,763 ) Distributions to owners, including noncontrolling interests — (102,330 ) (243,972 ) 230,713 (115,589 ) Capital contributions — 265,258 — (265,258 ) — Changes in intercompany balances with affiliates, net (2,657 ) — 2,657 — — Other, net (6,199 ) 2,520 1,332 (2,897 ) (5,244 ) Net cash flows provided by (used in) financing activities 211,794 165,439 (242,236 ) (37,442 ) 97,555 Net decrease in cash and cash equivalents (15,846 ) (11,292 ) (5,417 ) — (32,555 ) Cash and cash equivalents, beginning of period 20,437 27,507 58,716 — 106,660 Cash and cash equivalents, end of period $ 4,591 $ 16,215 $ 53,299 $ — $ 74,105 Condensed Consolidating Statement of Cash Flows - For the Six Months Ended June 30, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by (used in) operating activities $ (27,553 ) $ 172,907 $ 232,423 $ (126,382 ) $ 251,395 Cash flows from investing activities: Acquisitions and related expenses (51,852 ) (197,718 ) — 53,538 (196,032 ) Acquisition of property and equipment (4,490 ) (9,424 ) (18,751 ) — (32,665 ) Purchases of marketable securities — — (1,245 ) — (1,245 ) Maturities of marketable securities — — 2,988 — 2,988 Other — (1,441 ) (546 ) — (1,987 ) Net cash flows used in investing activities (56,342 ) (208,583 ) (17,554 ) 53,538 (228,941 ) Cash flows from financing activities: Proceeds from long-term borrowings — — 7,795 — 7,795 Repayment on long-term borrowings (4,350 ) — (5,938 ) — (10,288 ) Distributions to owners, including noncontrolling interests — (15,108 ) (212,307 ) 126,382 (101,033 ) Capital contributions — 51,852 — (51,852 ) — Changes in intercompany balances with affiliates, net 444 — (444 ) — — Other financing activities, net (2,892 ) 2,573 1,287 (1,686 ) (718 ) Net cash flows provided by (used in) financing activities (6,798 ) 39,317 (209,607 ) 72,844 (104,244 ) Net increase (decrease) in cash and cash equivalents (90,693 ) 3,641 5,262 — (81,790 ) Cash and cash equivalents, beginning of period 134,351 23,471 50,257 — 208,079 Cash and cash equivalents, end of period $ 43,658 $ 27,112 $ 55,519 $ — $ 126,289

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)center	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)center	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Variable Interest Entity [Line Items]
Number of ownership interests of less than 51% | center	24		24
Investments in unconsolidated affiliates	$ 179,056		$ 179,056		$ 169,170
Income (Loss) from Equity Method Investments	7,351	$ 3,989	13,930	$ 6,640
Net revenue	758,499	641,950	1,483,177	1,212,395
Prepaid and other current assets	74,565		74,565		75,771
Restricted Cash and Marketable Securities
Restricted cash and marketable securities, total	29,900		29,900		27,400
Restricted cash and investments, noncurrent	17,100		17,100		13,900
Restricted marketable securities	500		500		2,700
Variable Interest Entity, Primary Beneficiary, Aggregated Disclosure [Member]
Variable Interest Entity [Line Items]
Assets of VIEs	780,500		780,500		740,100
Liabilities of VIEs	297,700		297,700		299,000
Restricted use assets of VIEs	178,600		178,600		176,800
Debt of VIEs guaranteed by AmSurg	18,200		18,200		21,700
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Variable Interest Entity [Line Items]
Net revenue	5,300	3,800	11,600	7,200
Prepaid and other current assets	$ 9,200		$ 9,200		$ 6,000
Consolidated [Member]
Variable Interest Entity [Line Items]
Number of ownership interests of less than 51% | center	2		2
Ambulatory Services [Member]
Variable Interest Entity [Line Items]
Net revenue	$ 319,747	$ 310,991	$ 626,881	$ 594,901
Maximum [Member] | Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Variable Interest Entity [Line Items]
Percent of voting rights in unconsolidated affiliates			50.00%

Basis of Presentation - Reclass

Basis of Presentation - Reclassifications (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible assets, net	$ 1,679,275	$ 1,594,637
Long-term debt	2,581,043	2,357,956
Deferred debt issuance costs	$ (42,907)	(47,174)
Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible assets, net		(47,174)
Long-term debt		(47,174)
Accounting Standards Update 2015-03 [Member] | Intangible Assets, Net [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred debt issuance costs		(47,200)
Accounting Standards Update 2015-03 [Member] | Long-term Debt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred debt issuance costs		47,200
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible assets, net		1,641,811
Long-term debt		$ 2,405,130

Business Combinations (Details)

Business Combinations (Details) - Scenario, Forecast [Member] - Merger of AmSurg and Envision into New Amethyst [Member]	Dec. 31, 2016
AmSurg [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Number of shares to be issued for one share of acquiree's stock	1
AmSurg [Member] | Mandatory Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Number of shares to be issued for one share of acquiree's stock	1
Envision [Member]
Business Acquisition [Line Items]
Envision stockholders' percent of ownership in New Amethyst on date of merger	53.00%
Envision [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Number of shares to be issued for one share of acquiree's stock	0.334

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue, Major Customer [Line Items]
Provision for uncollectibles			$ (207,046)	$ (144,514)
Net revenue	$ 758,499	$ 641,950	$ 1,483,177	$ 1,212,395
Ambulatory Services [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues from governmental healthcare programs			26.00%	26.00%
Net revenue	319,747	310,991	$ 626,881	$ 594,901
Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	501,674	365,044	977,161	688,342
Contract and other revenue	38,411	31,698	74,076	62,687
Provision for uncollectibles	(101,333)	(65,783)	(194,941)	(133,535)
Net revenue	438,752	330,959	856,296	617,494
Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	61,775	45,967	120,549	87,296
Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	30,698	19,298	61,523	37,878
Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	337,553	254,481	661,724	474,599
Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	$ 71,648	$ 45,298	$ 133,365	$ 88,569
Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	100.00%	100.00%	100.00%	100.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	114.00%	110.00%	114.00%	111.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	14.00%	14.00%	14.00%	14.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	7.00%	6.00%	7.00%	6.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	77.00%	77.00%	77.00%	77.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	16.00%	14.00%	16.00%	14.00%
Contract and Other Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	9.00%	10.00%	9.00%	10.00%
Provision for Uncollectibles [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	23.00%	20.00%	23.00%	22.00%

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense			$ 207,046	$ 144,514
Allowances for accounts receivable	$ 208,780		$ 208,780		$ 167,411
Product Concentration Risk [Member] | Allowance for Doubtful Accounts [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts related to fee for service patient visits			82.00%		80.00%
Ambulatory Services [Member] | Other Operating Expenses [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	6,300	$ 4,700	$ 12,100	11,000
Physician Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 101,333	$ 65,783	$ 194,941	$ 133,535

Acquisitions and Disposals (Nar

Acquisitions and Disposals (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)physician_practicecenter	Jun. 30, 2015USD ($)physician_practicecenter	Dec. 31, 2015USD ($)
Business Acquisition [Line Items]
Acquisitions and related expenses, net			$ 281,113	$ 196,032
Net change in fair value of contingent consideration	$ (2,598)	$ 6,410	(2,598)	6,410
Transaction costs	5,135	$ 1,982	$ 6,525	$ 3,453
Ambulatory Services [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center			4	4
Acquisitions and related expenses, net			$ 25,700	$ 95,400
Ambulatory Services [Member] | Disposal Group, Not Discontinued Operations [Member]
Business Acquisition [Line Items]
Number of center disposals | center			2	0
Net gain from disposals			$ 3,300
Physician Services [Member]
Business Acquisition [Line Items]
Net change in fair value of contingent consideration			$ (2,600)
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Number of business acquisitions | physician_practice			6	4
Cash paid to acquire business			$ 255,400	$ 100,700
Deferred Consideration			$ 15,400
Deferred consideration period			2 years
Accrued liability, contingent consideration	1,000		$ 1,000		$ 5,500
Cash payment for previous acquisition			1,900
Contingent consideration arrangements, high	$ 1,000		1,000
Other Accrued Liabilities [Member] | Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Deferred Consideration			9,700
Other Long-term Liabilities [Member] | Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Deferred Consideration			$ 5,700

Acquisitions and Disposals (Rev

Acquisitions and Disposals (Revs and Earnings) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Business Acquisition [Line Items]
Net revenue	$ 758,499	$ 641,950	$ 1,483,177	$ 1,212,395
Net earnings	103,119	90,747	187,823	159,502
Less: Net earnings attributable to noncontrolling interests	57,050	57,072	110,891	104,789
Net earnings attributable to AmSurg Corp. shareholders	$ 46,069	$ 33,675	76,932	54,713
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Net revenue			12,714	48,042
Net earnings			2,198	9,101
Less: Net earnings attributable to noncontrolling interests			563	2,353
Net earnings attributable to AmSurg Corp. shareholders			$ 1,635	$ 6,748

Acquisitions and Disposals (Con

Acquisitions and Disposals (Consolidated Pro Forma Results Of Acquisition) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Business Combinations [Abstract]
Net revenue	$ 1,558,347	$ 1,488,632
Net earnings	198,383	221,765
Net earnings attributable to AmSurg Corp. common shareholders	$ 82,806	$ 68,374
Net earnings per common share, Basic (usd per share)	$ 1.53	$ 1.44
Net earnings per common share, Diluted (usd per share)	$ 1.52	$ 1.42

Acquisitions and Disposals (Fai

Acquisitions and Disposals (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 4,175,008	$ 3,970,210
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable	16,809
Other current assets	1,397
Property and equipment	4,258
Goodwill	209,194
Intangible assets	115,902
Other long-term assets	67
Accounts payable	(450)
Other accrued liabilities	(20,331)
Deferred income taxes	(20,706)
Other long-term liabilities	(5,700)
Long-term debt	(128)
Total fair value	300,312
Less: Fair value attributable to noncontrolling interests	19,199
Acquisition date fair value of total consideration transferred	$ 281,113

Investments in Unconsolidated46

Investments in Unconsolidated Affiliates (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)equity_method_investmentcenter	Jun. 30, 2015USD ($)equity_method_investmentcenter	Dec. 31, 2015USD ($)
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 179,056		$ 179,056		$ 169,170
Equity in earnings of unconsolidated affiliates	7,351	$ 3,989	13,930	$ 6,640
Net loss on deconsolidation	(700)	(3,000)	$ (700)	$ (3,300)
Joint Venture [Member] | Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center			1
Joint Venture [Member] | Ambulatory Services [Member] | Noncontrolling Interest In Centers [Member]
Schedule of Equity Method Investments [Line Items]
Number of separate equity method investments | equity_method_investment			1	1
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 1,800	$ 2,300	$ 1,800	$ 2,300
Controlling Interest [Member] | Joint Venture [Member] | Physician Services [Member]
Schedule of Equity Method Investments [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center			0	1

Prepaid and Other Current Ass47

Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Income Taxes Receivable	$ 16,241	$ 7,908
Prepaid expenses	22,104	18,900
Deferred compensation plan assets	23,530	16,623
Other	12,690	32,340
Total prepaid and other current assets	$ 74,565	$ 75,771

Goodwill And Intangible Asset48

Goodwill And Intangible Assets (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)physician_practicecenter	Jun. 30, 2015USD ($)physician_practicecenter	Dec. 31, 2015USD ($)
Segment Reporting Information [Line Items]
Goodwill	$ 4,175,008		$ 4,175,008		$ 3,970,210
Increase in goodwill			207,333
Goodwill deductible for tax purposes	100,900	$ 107,600	100,900	$ 107,600
Amortization of Intangible Assets	21,100	$ 14,700	41,500	$ 29,200
Estimated amortization of intangible assets, remainder of 2016	44,900		44,900
Estimated amortization of intangible assets, 2017	88,600		88,600
Estimated amortization of intangible assets, 2018	87,400		87,400
Estimated amortization of intangible assets, 2019	84,700		84,700
Estimated amortization of intangible assets, 2020	82,400		82,400
Estimated amortization of intangible assets, 2021	78,000		78,000
Estimated amortization of intangible assets, 2022 and thereafter	976,300		$ 976,300
Weighted average amortization period			17 years 328 days
Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Goodwill	209,194		$ 209,194
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Goodwill	2,100,000		2,100,000
Increase in goodwill			$ 38,400
Number of business acquisitions | center			4	4
Physician Services [Member]
Segment Reporting Information [Line Items]
Goodwill	$ 2,100,000		$ 2,100,000
Increase in goodwill			$ 166,400
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | physician_practice			6	4
Joint Venture [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center			1

Goodwill And Intangible Asset49

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Goodwill [Roll Forward]
Balance, beginning of period	$ 3,970,210
Goodwill acquired, including post acquisition adjustments	207,333
Goodwill disposed, including impact of deconsolidation transactions	(2,535)
Balance, end of period	$ 4,175,008

Goodwill And Intangible Asset50

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$ 236,995	$ 236,995
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,588,743	1,462,706
Accumulated Amortization	(146,463)	(105,064)
Net	1,442,280	1,357,642
Total intangible assets, gross carrying amount	1,825,738	1,699,701
Accumulated Amortization	(146,463)	(105,064)
Total intangible assets, net	1,679,275	1,594,637
Trade name [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	228,000	228,000
Restrictive covenant arrangements [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	8,995	8,995
Customer relationships with hospitals [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,494,790	1,379,977
Accumulated Amortization	(109,444)	(74,490)
Net	1,385,346	1,305,487
Accumulated Amortization	(109,444)	(74,490)
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	81,595	71,462
Accumulated Amortization	(33,500)	(28,125)
Net	48,095	43,337
Accumulated Amortization	(33,500)	(28,125)
Agreements, contracts, and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	12,358	11,267
Accumulated Amortization	(3,519)	(2,449)
Net	8,839	8,818
Accumulated Amortization	$ (3,519)	$ (2,449)

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Accrued professional liabilities	$ 14,541	$ 14,362
Contingent purchase price payable	1,000	5,509
Current income taxes payable	0	7,892
Refunds payable	29,626	48,415
Other	47,404	43,059
Total other accrued liabilities	$ 92,571	$ 119,237

Accrued Professional Liabilit52

Accrued Professional Liabilities - Components of Reserves (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Estimated losses under self-insured programs	$ 32,652	$ 30,748
Incurred but not reported losses	35,955	36,166
Total accrued professional liabilities	68,607	66,914
Less estimated losses payable within one year	14,541	14,362
Total	$ 54,066	$ 52,552

Accrued Professional Liabilit53

Accrued Professional Liabilities - Rollforward of Reserves (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Self Insurance Reserve [Roll Forward]
Balance at December 31, 2015	$ 66,914
Assumed liabilities through acquisitions	1,862
Provision related to current period reserves	10,037
Payments for current period reserves	(39)
Benefit related to changes in prior period reserves	(249)
Payments for prior period reserves	(6,307)
Other, net including post-acquisition adjustments	(3,611)
Balance at June 30, 2016	$ 68,607

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($) $ in Thousands	Jul. 16, 2014	Jun. 30, 2016	Dec. 31, 2015	Oct. 21, 2015	Nov. 20, 2012
Revolving Credit Facility [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		$ 400,000	$ 175,000
Term Loan and Credit Facility
Line of Credit Facility, Remaining Borrowing Capacity		$ 100,000
Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 870,000
Quarterly principal payment as a percent of face amount	0.25%
Annual principal payment	$ 8,700
Senior Secured Credit Facility - Term Loan [Member] | Base Rate [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Senior Secured Credit Facility - Term Loan [Member] | Base Rate [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
Senior Secured Credit Facility - Term Loan [Member] | LIBOR [Member]
Term Loan and Credit Facility
Floor rate	0.75%
Current variable rate		3.50%
Senior Secured Credit Facility - Term Loan [Member] | LIBOR [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
Senior Secured Credit Facility - Term Loan [Member] | LIBOR [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%
Revolving Credit Facility [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 500,000			$ 500,000
Increase to borrowing capacity from exercise of accordion feature				$ 200,000
Unused capacity commitment fee, percentage	0.375%
Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
Revolving Credit Facility [Member] | LIBOR [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
Revolving Credit Facility [Member] | LIBOR [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%
Fixed Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		$ 1,391,100
Long-term Debt, Fair Value		1,438,200
Variable Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt, Fair Value		1,253,600
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		250,000	250,000
Senior Unsecured Debt
Face amount					$ 250,000
Interest rate					5.625%
Senior Secured Debt
Face amount					$ 250,000
Interest rate					5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		$ 1,100,000	$ 1,100,000
Senior Unsecured Debt
Face amount	$ 1,100,000
Interest rate	5.625%
Redeemable principal percentage		35.00%
Senior Secured Debt
Face amount	$ 1,100,000
Interest rate	5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Period Prior to July 15, 2017 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount		105.625%

Long-Term Debt (Components Of L

Long-Term Debt (Components Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Other debt due through 2025	$ 23,920	$ 24,944
Capitalized lease arrangements due through 2026	18,202	18,613
Long-term debt and capitalized lease arrangements	2,644,722	2,425,507
Less current portion	20,772	20,377
Deferred Finance Costs, Noncurrent, Net	42,907	47,174
Long-term debt	2,581,043	2,357,956
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term Debt	400,000	175,000
Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt	852,600	856,950
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	250,000	250,000
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 1,100,000	$ 1,100,000

Long-Term Debt (Redemption Pric

Long-Term Debt (Redemption Price) (Details) - Senior Notes [Member]	6 Months Ended
	Jun. 30, 2016
2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	104.219%
2016 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	102.813%
2017 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	101.406%
2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	104.219%
2018 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	100.00%
2018 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	102.813%
2019 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	101.406%
2020 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	100.00%

Other Long-Term Liabilities (De

Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Other Long-Term Liabilities [Abstract]
Accrued professional liabilities	$ 54,066	$ 52,552
Deferred Rent	27,330	18,958
Tax-effected unrecognized benefits	3,426	3,426
Other	34,656	21,247
Other long-term liabilities	$ 119,478	$ 96,183

Shareholder's Equity (Narrative

Shareholder's Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / shares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / shares	Jun. 30, 2016USD ($)installment$ / sharesshares	Jun. 30, 2015USD ($)shares	Jun. 30, 2014shares
Common Stock:
Repurchase of common stock, shares						77,780	67,000
Repurchase of common stock | $						$ 5,700	$ 3,700
Mandatory Convertible Preferred Stock
Preferred stock dividends | $		$ (2,264)	$ (2,300)	$ (2,264)	$ (2,300)	$ (4,528)	$ (4,528)
Preferred Stock, Shares Outstanding	1,725,000	1,725,000				1,725,000
Stock Incentive Plans:
Number of shares authorized for grant under share incentive plan		3,200,000				3,200,000		1,200,000
Shares available for future grants/issuance under stock incentive plan		2,396,435				2,396,435
Unrecognized compensation cost on non vested awards | $		$ 45,600				$ 45,600
Weighted average period						1 year 2 months
Number of units granted						586,791
Grant date value of common stock | $ / shares						$ 74
Stock Options [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
Options term						10 years
Employees [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
Number of installments in restricted stock granted. | installment						3
Mandatory Convertible Preferred Stock [Member]
Stock Incentive Plans:
Number of anti-dilutive options				3,100,000			3,100,000
Stock Options [Member]
Stock Incentive Plans:
Number of anti-dilutive options		0		0		0	0
Common Stock [Member]
Issuance of stock (in shares)	5,835,000
Issuance of stock, price per share | $ / shares	$ 80
Stock offering expenses | $	$ 19,100
Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Dividend rate						5.25%
Initial liquidation preference (usd per share) | $ / shares		$ 100				$ 100
Consecutive trading day						20 days
Dividends declared (usd per share) | $ / shares		$ 1.3125	$ 1.3125	$ 1.3125	$ 1.3125
Minimum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate		1.8141				1.8141
Maximum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate		2.2222				2.2222
Performance-based Restricted Stock Units [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Number of units granted						74,752
Grant date value of common stock | $ / shares						$ 74.09
Performance goal period for vesting						1 year
Projected vesting percentage						150.00%
Performance-based Restricted Stock Units [Member] | Minimum [Member]
Stock Incentive Plans:
Projected vesting percentage						0.00%
Performance-based Restricted Stock Units [Member] | Maximum [Member]
Stock Incentive Plans:
Projected vesting percentage						150.00%

Shareholders' Equity (Share-Bas

Shareholders' Equity (Share-Based Activity) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Equity [Abstract]
Share-based compensation expense	$ 7,900	$ 3,883	$ 15,068	$ 7,592
Fair value of shares vested	1,282	1,746	18,243	13,220
Cash received from option exercises	174	334	450	2,080
Tax benefit from exercises of share-based awards	$ 129	$ 216	$ 3,734	$ 3,533

Shareholders Equity (Schedule O

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares at beginning of period, Number of Shares | shares	734,101
Shares granted, Number of Shares | shares	586,791
Shares vested, Number of Shares | shares	(249,421)
Shares forfeited, Number of Shares | shares	(5,407)
Non-vested shares at end of period, Number of Shares | shares	1,066,064
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares at beginning of period, Weighted Average Grant Price | $ / shares	$ 44.73
Shares granted, Weighted Average Grant Price | $ / shares	74
Shares vested, Weighted Average Grant Price | $ / shares	38.61
Shares forfeited, Weighted Average Grant Price | $ / shares	55.40
Non-vested shares at end of period, Weighted Average Grant Price | $ / shares	$ 62.22

Shareholder's Equity (Schedule

Shareholder's Equity (Schedule of Stock Option Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of Shares	33,751
Options exercised, Number of Shares	(19,718)
Options terminated, Number of Shares	(4,200)
Outstanding at end of period, Number of Shares	9,833	33,751
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period, Weighted Average Exercise Price	$ 22.98
Options exercised, Weighted Average Exercise Price	22.84
Options terminated, Weighted Average Exercise Price	21.07
Outstanding at end of period, Weighted Average Exercise Price	$ 24.09	$ 22.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period, Weighted Average Remaining Contractual Life (in years)	180 days	1 year 36 days
Outstanding at end of period, Weighted Average Remaining Contractual Life (in years)	180 days	1 year 36 days

Shareholder's Equity (Schedul62

Shareholder's Equity (Schedule of Stock Option Activity-Additional) (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Equity [Abstract]
Total intrinsic value with options exercised	$ 1
Aggregate intrinsic value of options outstanding	0.5
Total intrinsic value of options vested or expected to vest	$ 0.5
Vested or expected to vest at end of period, Number of Shares | shares	9,833
Vested or expected to vest at end of period, weighted average exercise price | $ / shares	$ 24.09
Vested or expected to vest at end of period, Weighted Average Remaining Contractual Life (in years)	180 days
Total Intrinsic value of options exercisable	$ 0.5
Exercisable at end of period, Number of Shares | shares	9,833
Exercisable at end of period, Weighted Average Exercise Price | $ / shares	$ 24.09
Exercisable at end of period, Weighted Average Remaining Contractual Life (in years)	180 days

Shareholder's Equity (Schedul63

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Convertible Preferred Dividends, Net of Tax	$ 2,264		$ 4,528
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (Numerator)	$ 43,805	$ 31,411	$ 72,404	$ 50,185
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (basic), shares (Denominator)	53,739	47,678	53,702	47,625
Earnings Per Share, Basic	$ 0.82	$ 0.66	$ 1.35	$ 1.05
Effect of dilutive securities, options and non-vested shares	3,588	421	3,527	377
Net Income (Loss) Attributable to Parent, Diluted	$ 46,069	$ 31,411	$ 76,932	$ 50,185
Net earnings (loss) from continuing operations attributable to AmSurg Corp. (diluted), shares (Denominator)	57,327	48,099	57,229	48,002
Earnings Per Share, Diluted	$ 0.80	$ 0.65	$ 1.34	$ 1.05
Mandatory Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive shares		3,100		3,100

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income tax paid, net of refunds	$ 45,726	$ 7,772

Commitments and Contingencies (

Commitments and Contingencies (Details) ft² in Thousands, $ in Millions	Jan. 16, 2015USD ($)ft²	Mar. 31, 2017ft²	Sep. 30, 2016ft²	Jun. 15, 2016USD ($)
Schedule Of Operating Leases Square Footage [Line Items]
Lease square footage | ft²	222
Annual rent expense	$ 2.9
Scenario, Forecast [Member]
Schedule Of Operating Leases Square Footage [Line Items]
Lease square footage | ft²		55	167
Merger of AmSurg and Envision into New Amethyst [Member]
Schedule Of Operating Leases Square Footage [Line Items]
Potential merger termination fee				$ 180
Potential merger termination reimbursement of expenses				$ 15

Segment Reporting (Details)

Segment Reporting (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)segment	Jun. 30, 2015USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			2
Segment Reporting Information [Line Items]
Net revenue	$ 758,499	$ 641,950	$ 1,483,177	$ 1,212,395
Adjusted EBITDA	149,243	127,972	269,343	221,727
Earnings from continuing operations attributable to noncontrolling interests	57,050	57,072	110,891	104,789
Interest expense, net	(31,913)	(30,182)	(62,723)	(60,429)
Depreciation and amortization	(30,054)	(23,612)	(59,126)	(46,430)
Share-based compensation	(7,900)	(3,883)	(15,068)	(7,592)
Net change in fair value of contingent consideration	2,598	(6,410)	2,598	(6,410)
Transaction costs	(5,135)	(1,982)	(6,525)	(3,453)
Deconsolidation And Disposals, Gain (Loss), Amount	2,595	(3,035)	2,595	(3,258)
Earnings before income taxes	136,484	115,940	241,985	198,944
Acquisition and Capital Expenditures	300,050	87,336	318,731	228,697
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Net revenue	319,747	310,991	626,881	594,901
Adjusted EBITDA	61,746	60,304	115,372	107,612
Acquisition and Capital Expenditures	35,031	64,514	43,401	118,610
Physician Services [Member]
Segment Reporting Information [Line Items]
Net revenue	438,752	330,959	856,296	617,494
Adjusted EBITDA	87,497	67,668	153,971	114,115
Net change in fair value of contingent consideration			2,600
Acquisition and Capital Expenditures	$ 265,019	$ 22,822	$ 275,330	$ 110,087

Financial Information for the67

Financial Information for the Company and Its Subsidiaries (Balance Sheets) (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 74,105	$ 106,660	$ 126,289	$ 208,079
Restricted cash and marketable securities	12,794	13,506
Accounts receivable, net	375,352	337,330
Supplies inventory	21,980	21,406
Prepaid and other current assets	74,565	75,771
Total current assets	558,796	554,673
Property and equipment, net	204,922	189,168
Investments in and receivables from unconsolidated affiliates	179,056	169,170
Goodwill	4,175,008	3,970,210
Intangible assets, net	1,679,275	1,594,637
Other assets	46,263	21,450
Total assets	6,843,320	6,499,308
Liabilities and Equity
Current portion of long-term debt	20,772	20,377
Accounts payable	30,721	32,561
Accrued salaries and benefits	186,908	202,537
Accrued interest	30,400	30,480
Other accrued liabilities	92,571	119,237
Total current liabilities	361,372	405,192
Long-term debt	2,581,043	2,357,956
Deferred income taxes	743,447	699,498
Other long-term liabilities	119,478	96,183
Intercompany payable	0	0
Noncontrolling interests – redeemable	177,845	175,732
Equity:
Total AmSurg Corp. equity	2,377,278	2,293,463
Noncontrolling interests – non-redeemable	482,857	471,284
Total equity	2,860,135	2,764,747
Total liabilities and equity	6,843,320	6,499,308
Consolidation, Eliminations [Member]
Assets
Cash and cash equivalents	0	0	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	(21,312)	(8,076)
Total current assets	(21,312)	(8,076)
Property and equipment, net	0	0
Investments in and receivables from unconsolidated affiliates	(6,848,343)	(6,507,128)
Goodwill	2,051,941	2,013,469
Intangible assets, net	0	0
Other assets	(1,999)	(1,998)
Total assets	(4,819,713)	(4,503,733)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(3,561)	(3,852)
Accrued salaries and benefits	0	0
Accrued interest	0	0
Other accrued liabilities	(17,751)	(4,224)
Total current liabilities	(21,312)	(8,076)
Long-term debt	(26,054)	(23,396)
Deferred income taxes	(1,998)	(1,998)
Other long-term liabilities	0	0
Intercompany payable	(1,228,157)	(1,228,157)
Noncontrolling interests – redeemable	116,959	112,672
Equity:
Total AmSurg Corp. equity	(4,092,881)	(3,778,478)
Noncontrolling interests – non-redeemable	433,730	423,700
Total equity	(3,659,151)	(3,354,778)
Total liabilities and equity	(4,819,713)	(4,503,733)
Parent Company [Member]
Assets
Cash and cash equivalents	4,591	20,437	43,658	134,351
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	45,542	28,739
Total current assets	50,133	49,176
Property and equipment, net	11,877	12,515
Investments in and receivables from unconsolidated affiliates	5,219,975	4,901,026
Goodwill	0	0
Intangible assets, net	13,037	12,780
Other assets	7,186	4,653
Total assets	5,302,208	4,980,150
Liabilities and Equity
Current portion of long-term debt	8,700	8,700
Accounts payable	3,073	2,816
Accrued salaries and benefits	29,533	31,510
Accrued interest	30,386	30,463
Other accrued liabilities	5,171	13,962
Total current liabilities	76,863	87,451
Long-term debt	2,550,996	2,326,103
Deferred income taxes	288,503	268,573
Other long-term liabilities	8,568	4,560
Intercompany payable	0	0
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	2,377,278	2,293,463
Noncontrolling interests – non-redeemable	0	0
Total equity	2,377,278	2,293,463
Total liabilities and equity	5,302,208	4,980,150
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	16,215	27,507	27,112	23,471
Restricted cash and marketable securities	0	0
Accounts receivable, net	258,863	223,434
Supplies inventory	0	0
Prepaid and other current assets	24,074	39,046
Total current assets	299,152	289,987
Property and equipment, net	27,822	14,601
Investments in and receivables from unconsolidated affiliates	1,807,424	1,775,272
Goodwill	2,123,067	1,956,741
Intangible assets, net	1,664,313	1,579,537
Other assets	20,825	1,717
Total assets	5,942,603	5,617,855
Liabilities and Equity
Current portion of long-term debt	20	0
Accounts payable	1,640	3,760
Accrued salaries and benefits	140,149	158,705
Accrued interest	0	0
Other accrued liabilities	69,166	76,590
Total current liabilities	210,975	239,055
Long-term debt	36	0
Deferred income taxes	456,942	432,923
Other long-term liabilities	76,144	71,509
Intercompany payable	1,228,157	1,228,157
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	3,967,431	3,646,211
Noncontrolling interests – non-redeemable	2,918	0
Total equity	3,970,349	3,646,211
Total liabilities and equity	5,942,603	5,617,855
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	53,299	58,716	$ 55,519	$ 50,257
Restricted cash and marketable securities	12,794	13,506
Accounts receivable, net	116,489	113,896
Supplies inventory	21,980	21,406
Prepaid and other current assets	26,261	16,062
Total current assets	230,823	223,586
Property and equipment, net	165,223	162,052
Investments in and receivables from unconsolidated affiliates	0	0
Goodwill	0	0
Intangible assets, net	1,925	2,320
Other assets	20,251	17,078
Total assets	418,222	405,036
Liabilities and Equity
Current portion of long-term debt	12,052	11,677
Accounts payable	29,569	29,837
Accrued salaries and benefits	17,226	12,322
Accrued interest	14	17
Other accrued liabilities	35,985	32,909
Total current liabilities	94,846	86,762
Long-term debt	56,065	55,249
Deferred income taxes	0	0
Other long-term liabilities	34,766	20,114
Intercompany payable	0	0
Noncontrolling interests – redeemable	60,886	63,060
Equity:
Total AmSurg Corp. equity	125,450	132,267
Noncontrolling interests – non-redeemable	46,209	47,584
Total equity	171,659	179,851
Total liabilities and equity	$ 418,222	$ 405,036

Financial Information for the68

Financial Information for the Company and Its Subsidiaries (Income Statements) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Financial Statements, Captions [Line Items]
Net revenue	$ 758,499		$ 641,950		$ 1,483,177	$ 1,212,395
Operating expenses:
Salaries and benefits	404,011		320,396		813,850	622,575
Supply cost	49,703		45,790		96,666	88,374
Other operating expenses	111,145		105,002		218,827	195,572
Transaction costs	5,135		1,982		6,525	3,453
Depreciation and amortization	30,054		23,612		59,126	46,430
Total operating expenses	600,048		496,782		1,194,994	956,404
Net gain (loss) on disposals and deconsolidations	2,595		(3,035)		2,595	(3,258)
Equity in earnings of unconsolidated affiliates	7,351		3,989		13,930	6,640
Operating income	168,397		146,122		304,708	259,373
Interest expense (income), net	31,913		30,182		62,723	60,429
Earnings before income taxes	136,484		115,940		241,985	198,944
Income tax expense	33,365		25,193		54,162	39,442
Net earnings	103,119		90,747		187,823	159,502
Less net earnings attributable to noncontrolling interests	57,050		57,072		110,891	104,789
Net earnings attributable to AmSurg Corp. shareholders	46,069		33,675		76,932	54,713
Preferred stock dividends	(2,264)	$ (2,300)	(2,264)	$ (2,300)	(4,528)	(4,528)
Net earnings attributable to AmSurg Corp. common shareholders	43,805		31,411		72,404	50,185
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	(10,290)		(9,488)		(20,598)	(18,342)
Operating expenses:
Salaries and benefits	(135)		(124)		(268)	(252)
Supply cost	(20)		(34)		(33)	(34)
Other operating expenses	(10,135)		(9,330)		(20,297)	(18,056)
Transaction costs	0		0		0	0
Depreciation and amortization	0		0		0	0
Total operating expenses	(10,290)		(9,488)		(20,598)	(18,342)
Net gain (loss) on disposals and deconsolidations	0		0		0	188
Equity in earnings of unconsolidated affiliates	(149,288)		(137,455)		(277,187)	(249,774)
Operating income	(149,288)		(137,455)		(277,187)	(249,586)
Interest expense (income), net	0		0		0	0
Earnings before income taxes	(149,288)		(137,455)		(277,187)	(249,586)
Income tax expense	0		0		0	0
Net earnings	(149,288)		(137,455)		(277,187)	(249,586)
Less net earnings attributable to noncontrolling interests	0		0		0	0
Net earnings attributable to AmSurg Corp. shareholders	(149,288)		(137,455)		(277,187)	(249,586)
Preferred stock dividends	0		0		0	0
Net earnings attributable to AmSurg Corp. common shareholders	(149,288)		(137,455)		(277,187)	(249,586)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	7,700		7,079		16,244	14,170
Operating expenses:
Salaries and benefits	22,246		15,511		46,341	33,154
Supply cost	0		0		0	0
Other operating expenses	6,034		5,783		13,652	12,417
Transaction costs	2,099		324		2,276	592
Depreciation and amortization	1,103		1,056		2,175	1,890
Total operating expenses	31,482		22,674		64,444	48,053
Net gain (loss) on disposals and deconsolidations	0		0		0	(188)
Equity in earnings of unconsolidated affiliates	87,700		76,931		156,742	137,318
Operating income	63,918		61,336		108,542	103,247
Interest expense (income), net	(4,215)		11,978		(7,034)	23,864
Earnings before income taxes	68,133		49,358		115,576	79,383
Income tax expense	22,064		15,683		38,644	24,670
Net earnings	46,069		33,675		76,932	54,713
Less net earnings attributable to noncontrolling interests	0		0		0	0
Net earnings attributable to AmSurg Corp. shareholders	46,069		33,675		76,932	54,713
Preferred stock dividends	(2,264)		(2,264)		(4,528)	(4,528)
Net earnings attributable to AmSurg Corp. common shareholders	43,805		31,411		72,404	50,185
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	437,042		329,579		852,872	615,158
Operating expenses:
Salaries and benefits	305,173		228,618		614,753	440,219
Supply cost	1,145		489		2,152	885
Other operating expenses	44,213		42,099		87,552	71,710
Transaction costs	3,036		1,658		4,249	2,861
Depreciation and amortization	21,192		14,617		41,528	28,924
Total operating expenses	374,759		287,481		750,234	544,599
Net gain (loss) on disposals and deconsolidations	2,857		(3,035)		2,857	(3,223)
Equity in earnings of unconsolidated affiliates	68,939		64,513		134,375	119,096
Operating income	134,079		103,576		239,870	186,432
Interest expense (income), net	35,528		17,624		68,504	35,378
Earnings before income taxes	98,551		85,952		171,366	151,054
Income tax expense	10,858		9,021		14,632	13,924
Net earnings	87,693		76,931		156,734	137,130
Less net earnings attributable to noncontrolling interests	(7)		0		(7)	0
Net earnings attributable to AmSurg Corp. shareholders	87,700		76,931		156,741	137,130
Preferred stock dividends	0		0		0	0
Net earnings attributable to AmSurg Corp. common shareholders	87,700		76,931		156,741	137,130
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	324,047		314,780		634,659	601,409
Operating expenses:
Salaries and benefits	76,727		76,391		153,024	149,454
Supply cost	48,578		45,335		94,547	87,523
Other operating expenses	71,033		66,450		137,920	129,501
Transaction costs	0		0		0	0
Depreciation and amortization	7,759		7,939		15,423	15,616
Total operating expenses	204,097		196,115		400,914	382,094
Net gain (loss) on disposals and deconsolidations	(262)		0		(262)	(35)
Equity in earnings of unconsolidated affiliates	0		0		0	0
Operating income	119,688		118,665		233,483	219,280
Interest expense (income), net	600		580		1,253	1,187
Earnings before income taxes	119,088		118,085		232,230	218,093
Income tax expense	443		489		886	848
Net earnings	118,645		117,596		231,344	217,245
Less net earnings attributable to noncontrolling interests	57,057		57,072		110,898	104,789
Net earnings attributable to AmSurg Corp. shareholders	61,588		60,524		120,446	112,456
Preferred stock dividends	0		0		0	0
Net earnings attributable to AmSurg Corp. common shareholders	$ 61,588		$ 60,524		$ 120,446	$ 112,456

Financial Information for the69

Financial Information for the Company and Its Subsidiaries (Cash Flow Statements) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net cash flows provided by operating activities	$ 195,105	$ 251,395
Cash flows from investing activities:
Acquisitions and related expenses	(281,113)	(196,032)
Acquisition of property and equipment	(37,618)	(32,665)
Proceeds from sale of interests in surgery centers	25	0
Purchases of marketable securities	(498)	(1,245)
Maturities of marketable securities	2,738	2,988
Other	(8,749)	(1,987)
Net cash flows used in investing activities	(325,215)	(228,941)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	317,151	7,795
Repayment on long-term borrowings and revolving credit facility	(98,763)	(10,288)
Distributions to owners, including noncontrolling interests	(115,589)	(101,033)
Capital contributions	0	0
Changes in intercompany balances with affiliates, net	0	0
Other, net	(5,244)	(718)
Net cash flows provided by (used in) financing activities	97,555	(104,244)
Net decrease in cash and cash equivalents	(32,555)	(81,790)
Cash and cash equivalents, beginning of period	106,660	208,079
Cash and cash equivalents, end of period	74,105	126,289
Consolidation, Eliminations [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	(230,713)	(126,382)
Cash flows from investing activities:
Acquisitions and related expenses	268,155	53,538
Acquisition of property and equipment	0	0
Proceeds from sale of interests in surgery centers	0
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	0	0
Net cash flows used in investing activities	268,155	53,538
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0
Repayment on long-term borrowings and revolving credit facility	0	0
Distributions to owners, including noncontrolling interests	230,713	126,382
Capital contributions	(265,258)	(51,852)
Changes in intercompany balances with affiliates, net	0	0
Other, net	(2,897)	(1,686)
Net cash flows provided by (used in) financing activities	(37,442)	72,844
Net decrease in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	39,294	(27,553)
Cash flows from investing activities:
Acquisitions and related expenses	(265,258)	(51,852)
Acquisition of property and equipment	(1,676)	(4,490)
Proceeds from sale of interests in surgery centers	0
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	0	0
Net cash flows used in investing activities	(266,934)	(56,342)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	313,000	0
Repayment on long-term borrowings and revolving credit facility	(92,350)	(4,350)
Distributions to owners, including noncontrolling interests	0	0
Capital contributions	0	0
Changes in intercompany balances with affiliates, net	(2,657)	444
Other, net	(6,199)	(2,892)
Net cash flows provided by (used in) financing activities	211,794	(6,798)
Net decrease in cash and cash equivalents	(15,846)	(90,693)
Cash and cash equivalents, beginning of period	20,437	134,351
Cash and cash equivalents, end of period	4,591	43,658
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	131,227	172,907
Cash flows from investing activities:
Acquisitions and related expenses	(284,010)	(197,718)
Acquisition of property and equipment	(19,916)	(9,424)
Proceeds from sale of interests in surgery centers	25
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	(4,057)	(1,441)
Net cash flows used in investing activities	(307,958)	(208,583)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0
Repayment on long-term borrowings and revolving credit facility	(9)	0
Distributions to owners, including noncontrolling interests	(102,330)	(15,108)
Capital contributions	265,258	51,852
Changes in intercompany balances with affiliates, net	0	0
Other, net	2,520	2,573
Net cash flows provided by (used in) financing activities	165,439	39,317
Net decrease in cash and cash equivalents	(11,292)	3,641
Cash and cash equivalents, beginning of period	27,507	23,471
Cash and cash equivalents, end of period	16,215	27,112
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	255,297	232,423
Cash flows from investing activities:
Acquisitions and related expenses	0	0
Acquisition of property and equipment	(16,026)	(18,751)
Proceeds from sale of interests in surgery centers	0
Purchases of marketable securities	(498)	(1,245)
Maturities of marketable securities	2,738	2,988
Other	(4,692)	(546)
Net cash flows used in investing activities	(18,478)	(17,554)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	4,151	7,795
Repayment on long-term borrowings and revolving credit facility	(6,404)	(5,938)
Distributions to owners, including noncontrolling interests	(243,972)	(212,307)
Capital contributions	0	0
Changes in intercompany balances with affiliates, net	2,657	(444)
Other, net	1,332	1,287
Net cash flows provided by (used in) financing activities	(242,236)	(209,607)
Net decrease in cash and cash equivalents	(5,417)	5,262
Cash and cash equivalents, beginning of period	58,716	50,257
Cash and cash equivalents, end of period	$ 53,299	$ 55,519